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Abstract: Dementia represents a heterogeneous term that has evolved to describe the behav-
ioral syndromes associated with a variety of clinical and neuropathological changes during 
continuing degenerative disease of the brain. As such, there lacks a clear consensus regarding 
the neuropsychological and other constituent characteristics associated with various cere-
brovascular changes in this disease process. But increasing this knowledge has given more 
insights into memory deterioration in patients suffering from Alzheimer’s disease and other 
subtypes of dementia. The author reviews current knowledge of the physiological coupling 
between cerebral blood ﬂ  ow and metabolism in the light of state-of-the-art-imaging methods 
and its changes in dementia with special reference to Alzheimer’s disease. Different imag-
ing techniques are discussed with respect to their visualizing effect of biochemical, cellular, 
and/or structural changes in dementia. The pathophysiology of dementia in advanced age is 
becoming increasingly understood by revealing the underlying basis of neuropsychological 
changes with current imaging techniques, genetic and pathological features, which suggests 
that alterations of (neuro)vascular regulatory mechanisms may lead to brain dysfunction 
and disease. The current view is that cerebrovascular deregulation is seen as a contributor to 
cerebrovascular pathologies, such as stroke, but also to neurodegenerative conditions, such 
as Alzheimer’s disease. The better understanding of these (patho)physiological mechanisms 
may open an approach to new interventional strategies in dementia to enhance neurovascular 
repair and to protect neurovascular coupling.
Keywords: imaging, cognitive impairment, Alzheimer’s disease, cerebrovascular disease, 
neurovascular coupling
Introduction
Dementia represents a general term used to describe a chronic and substantial decline 
in two or more areas of cognitive function related to cellular and subcellular changes 
in the brain (Erkinjuntti et al 1997) underlining the multifactor origin of dementia 
syndrome (Pohjasvaara et al 2000). Imaging techniques (IT) supporting the diagnosis 
of different dementia subgroups of are moving from a negative, exclusionary role 
(American Academy of Neurology 1994) to one that reveals positive diagnostic, 
therapeutic, and/or prognostic value. FIT can offer an important impact in the treatment 
of dementia (Schaller et al 2003).
Cerebrovascular changes (CVC) represent a common symptom of the physi-
ological aging process (Schaller 2004a, 2004b, 2005; Schaller et al 2004a, 2004b), 
and cerebrovascular risk factors are strongly associated with dementia including 
Alzheimer’s disease (AD) (Cummings 1994; Desmond 1996; Skoog 1998). About 
40% of the population who met the diagnostic criteria for probable AD also show 
markers for cerebrovascular disease (CVD) (Desmond 1996; Iadecola 2003; Jell-
inger et al 2003; Kleindienst et al 2004a, 2004b). In addition, different well recog-
nized risk factors for CVD are strongly associated with AD and have elucidated the Neuropsychiatric Disease and Treatment 2008:4(3) 586
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impact of cerebrovascular lesions on the development and 
progression of dementia in AD (Jellinger et al 2002, 2003) 
suggesting that there exists a relationship between elevated 
midlife blood pressure and late-life AD (Forette et al 1998). 
With the recent availability of several effective pharmaceuti-
cal agents for treatment of dementia undergoing clinical trials 
(Tang et al 2006), a new area will be entered emphasizing 
the increasing need to diagnose dementia in its more earlier 
stages (Zanetti 1998), so that new IT gain increased impor-
tance in last years (Hillman et al 1997; Paris 1997). FIT 
represent the potential to enable identiﬁ  cation of more subtle 
pathological (sub)cellular changes earlier during the disease 
course (Buckner et al 2000; Bondi et al 2005). To better use 
these new diagnostic modalities, a thorough understanding 
of the physiological changes in the aging process and of the 
pathophysiological steps in dementia is needed.
Physiological background as related 
to dementia
The coupling between neuronal activity 
and cerebral metabolism
Current physiological-based hypotheses regarding the 
activity-/metabolism-coupling in different activated states of 
the brain (Figure 1), whether activated neurons in the brain 
signiﬁ  cantly increase their consumption of oxygen (cerebral 
metabolic rate, CMRO2) or whether they exploit anaerobic 
metabolism for energy production, have been disputed 
(Schaller et al 2003). In particular, glutamate, released by 
activated neurons, would be the pivotal element coupling 
glucose consumption (CMRglc) to excitatory neuronal activ-
ity (NA) (Pellerin et al 1994) involving glutamate uptake 
into astrocytes, resulting in an increased intracellular Na+ 
concentration ([Na+
i ]) and activation of the Na+/K+-ATPase 
(Chatton et al 2003; Bernardinelli 2004). Such increased 
metabolic demand linked to disruption of Na+ homeostasis 
may activate glucose uptake and glycolysis in astrocytes 
(Chatton et al 2003). Therefore, astrocytes appear to function 
as a network for concentrated neurometabolic coupling 
through Na+
i gerneration and increased metabolic turnover 
(Bernardinelli et al 2004). Indeed, a stoichiometric relation 
has been reported between glutamate- and glucose-uptake 
by cultured astrocytes and likewise between glutamate 
cycling and CMRglc in mice cortex (Pellerin et al 1994). This 
proposed model is consistent with the view that during NA, 
glutamate uptake into astrocytes leads to increased CMRglc 
and lactate production, which can be subsequently used by 
neurons to meet their energy needs (Magistrettti 2000).
NA applies to a spectrum of energy requiring processes 
including action potential propagation, neurotransmitter 
release and up-take, vesicular recycling, and maintenance of 
membrane potential, providing a conceptual framework for 
the interpretation of new experimental data on the molecu-
lar aspects of cerebral energy metabolism (Tsacopoulos 
et al 1996). All these processes are involved in short-term 
neuronal information encoding, but the relative distribution 
of energy among them and how the different subclasses of 
neurons in a speciﬁ  c cortical region contribute to the overall 
energy consumption process remains an open question. At 
present, FIT identiﬁ  es the location of changes in NA, but 
provides still no insight into the total NA involved in a pro-
cess (Magistretti 2000; Magistretti et al 1999). In addition, 
the stoichiometric relationship between glutamate cycling 
and oxidative glucose metabolism argues for a quantitative 
coupling between NA and cerebral metabolism and would 
be in favor of metabolism as an index of NA (Magistretti 
et al 1999).
γ-Aminobutric acid (GABA) is the major inhibitory 
neurotransmitter in the central nervous system (CNS). 
GABA does not couple inhibitory NA with CMRglc, as does 
glutamate for excitatory neurotransmission, and suggest that 
GABA-mediated synaptic transmission does not contribute 
directly to signals in IT based on deoxyglucose (Chatton 
2003). In addition, anatomical and physiological arguments 
have been put forward to support the physiological concept 
that inhibition might involve lower metabolic demands 
(Magistretti 2000; Chatton 2003). Based on their reduced 
number, strategic position, and increased efﬁ  ciency, inhibi-
tion provided by synapses from GABAergic interneurons 
in the cortex might simply involve less energy expenditure 
upon activation than the excitatory drive (Koistinaho 2003). 
Thus glutamate, by activating GABA neurons, could lead 
to an overall inhibitory NA in a speciﬁ  c cortical area; yet 
glutamate release and uptake by astrocytes would stimulate 
glycolysis in astrocytes and constitute a sufﬁ  cient signal 
Figure 1 Neurobarrier coupling in the brain: The potential neurovascular and 
neurometabolic coupling (Leybaert 2005).
Abbreviation: BBB, blood–brain barrier.Neuropsychiatric Disease and Treatment 2008:4(3) 587
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coding for increased activity of GABAergic neurons as 
well (Chatton et al 2003). It would therefore appear that 
the most relevant, and possibly sufﬁ  cient imaging signal, 
linking NA (both excitatory and inhibitory) with metabolism 
is glutamate, which would mediate the appropriate meta-
bolic coupling both for excitatory and inhibitory neurons 
(Magistretti 2000).
The neurovascular coupling
Experimental studies provide evidence for a cascade of physi-
ological events for NVC whereby glutamate, leaking from 
active synapses, activates glutamate receptors on astrocyte 
membranes, leading to an elevation of intracellular Ca2+
[Ca2+
i  ], which in turn leads to the biochemical production 
and release of eicosanioids, which represent potent vaso-
dilators (Bonvento et al 2002). Interruption of any stage of 
this cascade reduces the cerebral blood ﬂ  ow (CBF) response 
severely, without affecting the neural response (Magistretti 
2000; Bonvento et al 2002).
Advances in this research ﬁ  eld have demonstrated that 
release of the major excitatory neurotransmitter glutamate 
initiates physiologically diverse signaling processes between 
neurons and astrocytes, and that this signaling could be cru-
cial for the occurrence of molecular imaging signals, although 
the neurovascular importance of these mechanisms is not 
clear (Bonvento et al 2002). Re-uptake of glutamate from the 
synaptic cleft into astrocytes is mediated by the speciﬁ  c high-
afﬁ  nity glial transporters GLAST (glial glutamate aspartate 
transporter) and GLT-1 (glutamate transporter 1), which are 
particularly enriched in brain areas with high glutamatergic 
activity and are essential to maintain glutamate levels below 
neurotoxicity limits (Schmidt et al 2004).
A positive linear correlation has been reported between 
the integrated electrophysiological activities, ie, summed 
evoked potentials (EP), at different frequencies of NA 
stimulation and CBF response (Ances et al 2000b), demon-
strating that CBF response did not depend on NA intensity 
when duration was held constant (time-intensity separability) 
(Ances et al 2000b). However, mathematical modeling of the 
relationship between CBF and electrophysiological response 
to somatosensory stimulation revealed not only a linear but 
also a nonlinear component in this NVC (Ances et al 2000b). 
Indeed, changing the stimulus duration, but not the inten-
sity, results in a different pattern of responses for CBF and 
somatosensory EP, each one exhibiting maximal amplitude 
for different stimulus durations (Ances et al 2000b). More-
over, activation-ﬂ  ow coupling seems to be dependent on the 
interstimulus interval (Ances et al 2000a): CBF response 
is less important when interstimulus time is short, while 
somatosensory EP’s response is not altered, suggesting that 
hemodynamic response but not neuronal response is refrac-
tory (Figure 2). The spatial extent of activation in functional 
magnetic resonance imaging (fMRI) experiments has been 
found to correlate to a reasonable extent with NA measured 
neurophysiologically, considering the differences between 
these IT (Detre et al 2002).
Glutamate might not be the only neurotransmitter that 
is involved in NVC via glutamate transporters, an increased 
Na+
i followed by activation of a speciﬁ  c glial Na+/K+-ATPase 
isozyme (Cholet et al 2002). Acetylcholine (ACh) that is 
produced by the basal forebrain neurons increases CBF in 
speciﬁ  c cortical (mainly frontoparietal) and subcortical areas 
(Atochin et al 2003). This subcellular effect might be due 
to the direct contact of basal forebrain neurons or due to the 
presence of cholinergic receptors on nitric oxide synthetase 
(NOS)-containing neurons (Atochin et al 2003) and underlies 
a physiological age-related impairment of NVC (Hock et al 
1995). The neuronal system also plays an important role in 
the coupling mechanism between NA and functional CBF 
response (Tsukada et al 2000) being attributable to the altera-
tions of mechanisms of coupling via the cholinergic system 
not only in AD, but also in physiological aging (Meyer 
et al 2002). Although the exact (sub)cellular mechanisms 
are unclear, pathological depletion of Ach is therefore also 
encountered in vascular dementia. It seems that vascular 
lesions damage cholinergic neurons (Meyer et al 2002).
The coupling between cerebral blood 
ﬂ  ow and cerebral metabolism
The hypothesis of NVC is proposed initially by Roy and 
Sherrington in 1890 (cited in Weller et al 2002) that activ-
ity-induced increase in glycolysis mediates the increase in 
CBF by mechanisms linked through the near-equilibrium 
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relationsship between cytosolic NADH/NAD+ and the 
lactate/pyravat ratios (Wolf et al 1997). There is evidence 
that the intracellular NAD+/NADH and the related extra-
cellular ratio of lactate to pyruvate play an importance as 
products of cerebral metabolism as well as chemical stimuli 
are key factors that determine CBF rate (Wolf et al 1997; 
Ames III 2000). CBF in the activated brain is regulated by 
the need to support very speciﬁ  c and vital reactions such as 
glutamte uptake and cycling by astrocytes (Wolf et al 1997). 
CBF, however, may increase without signiﬁ  cant change in 
local metabolism, and may increase much faster than the 
accumulation of the metabolic end-products (Magistretti 
et al 1999). The regulation of coupling should thus involve 
physiological mechanisms that are independent of ener-
getic substrates (Magistretti 2000). CBF changes in the 
physiologically stimulated brain is thus related to changes 
in glyclolysis predominantly in astrocytes and is aimed to 
balance the cytosolic NADH/NAD+ ratio (Wolf et al 1997). 
Neurogenic stimulation via perivascular nerve endings may 
act as a rapid initiator, to induce a moment-to-moment 
dynamic CBF adjustment to the metabolic demands, and 
further maintenance of these adjusted parameters is ensured 
by metabolic and chemical factors (Sandor 1999; Zonta et al 
2003). Constrictions appears spatially restricted, maximal at 
the level of neurite apposition, and is associated with con-
traction of surronding smooth muscle cells, providing the 
ﬁ  rst evidence for neuronal regulation of vascular sphincters 
(Riddle et al 2003; Cauli et al 2004). Vascular cells are 
functionally linked to the neural tissue (Zheng et al 1991), 
making them essential members of the diverse family of brain 
cells that together constitute the neurovascular unit: Peri-
vascular nerve endings were identiﬁ  ed in the outer smooth 
muscle layer of the cerebral arteries, arterioles and veins 
(Sandor 1999). Their axon terminals contain a large variety 
of neurotransmitters, often co-localized in synaptic vesicles 
(Sandor 1999). Stimulation of these nerves results in a release 
of transmitters into narrow neuromuscular synaptic clefts of 
the cerebrovascular smooth muscles, close to speciﬁ  c recep-
tor sites in the vessel wall (Sandor 1999). Several vasoactive 
molecules have been implicated in two types of regulation: 
(i) a local metabolic regulation exerted by NO, arachidonic 
acid derivates and adenosine or (ii) a loco-regional neuro-
genic regulation exerted by classical neurotransmitters and 
peptidergic neuromodulators (Roland et al 1987). Based on 
the fact that vascular responses to NA are extremely fast, 
neurogenic regulation and NO appears to represent major 
candidates for a role in the dynamic adaptation of CBF 
(Ogawa et al 1996). This context is elegantly illustrated in 
that NA causes vasodilatation through the ability of speciﬁ  c 
subsets of NO-producing GABA interneurons to transmute 
neuronal signals into vascular responses and further suggest 
that they could act as local integrators of NVC (Ranicillac 
et al 1996; Cauli 2004; Zlokovic 2005).
Highly regulated metabolic interactions occur between 
neurons and astrocytes, providing a conceptual framework for 
the interpretation of new experimental data on the molecu-
lar aspects of brain energy metabolism (Magistretti 2000). 
Through the use of autoradiographic techniques in animal-
model’s brain activity at rest, a linear relationship between 
CBF and CMRglc has been demonstrated (Zlokovic et al 
2004). A quite similar correlation has been found between 
CBF and CMRO2 at the resting state (Roland et al 1987). 
Such a relationship between CBF and neuronal metabolism, 
so-called “ﬂ  ow-/metabolism-coupling,” is observed what-
ever technique or species is used (Gsell et al 2000; Snyder 
et al 2005). Although the existence of a ﬂ  ow-/metabolism-
coupling at rest is well accepted, the parallelism between 
CBF and cerebral metabolism appears to be far from clear 
during NA paradigms. There is considerable heterogeneity, 
for example, in the density of brain capillaries and in the 
distribution of mitochondria responsible for aerobic metabo-
lism (Nag 2003). Coupling between CBF and CMRglc is quite 
well preserved in a vast majority of cerebral regions that are 
activated following either mechanical or electrical stimula-
tion under experimental conditions, but several uncoupled 
situations have been observed in subcortical regions such as 
the thalamus, a brain region in which the CBF response is 
found to largely exceed that one of CMRglc under physiologi-
cal conditions (Ueki et al 1988; Buxton et al 2000; Gsell et al 
2005). Hemodynamic responses correlate better with local 
mean ﬁ  eld EP, rather then local spiking rates, suggesting 
that CVC is dominantly driven by input synaptic activity 
rather than output spiking activity (Lauritzen et al 2003). The 
primary expenditure of energy is required to restore the ion 
gradients degraded during NA (Magistretti et al 1999; Buxton 
et al 2004). The intracellular – extracellular Na+-gradient is 
far from equilibrium, so pumping Na+ against this gradient 
represents a strongly uphill reaction in a thermodynamic 
sense (Buxton et al 2004). For this reason, the most costly 
aspect of NA is likely to be excitatory synaptic activity in 
which glutamate opens Na+ channels (Magistretti 2000; 
Buxton et al 2004). Indeed, the action of the Na+/K+ pump 
is thought to consume a large fraction of the ATP energy 
budget in the brain (Magistretti et al 1999; Ames III 2000). 
The maintenance of such an energy state despite constant 
metabolic rate in the somatosensory cortex suggests that the Neuropsychiatric Disease and Treatment 2008:4(3) 589
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generation of EP does not require measurable amounts of 
energy under pathological conditions, like in postischemia 
or poststroke conditions (Ueki et al 1988). Several techni-
cal points have been proposed to explain such pathological 
situations of uncoupling between CBF and CMRglc under 
experimental conditions and to exclude nonpathological 
conditions: (i) a difference of the temporal resolution between 
imaging techniques for CBF versus CMRglc; (ii) a low spatial 
resolution not allowing the detection of very small regions 
of interest; and (iii) a different size of the activation foci for 
CBF and cerebral metabolism. For this latter point, a larger 
activation is needed in comparison to a region delineated by 
the CMRglc changes; this can also result in misleading inter-
pretations (Howard et al 1998). Therefore, the hypothesis 
of a nonlinear coupling between CBF and CMR02 has been 
proposed (Magistretti et al 1999): With increased NA, CBF 
increases substantially, while CMR02 increases only mod-
erately, so the oxygen extraction fraction (OEF) is reduced 
(Forette et al 1998). In addition, a nonunit gain relationship 
is actually expected due to the diffusion limitation of oxygen 
supply. However, astrocytic lactate can replace glucose as an 
energetic supply for neurons during activation has suggested 
that, at least, part of the glucidic metabolism could be anaero-
bic recycling NAD+ via the reduction of pyruvate to lactate 
despite the presence of sufﬁ  cient oxygen and export the 
lactate (Pantel et al 1998). It seems that not all carbohydrate 
taken up by the brain is oxidized during activation, as brain 
lactate metabolism appears to lower the balance of O2-to-
carbohydrate uptake (Ide et al 2000). Lactate seems then to 
be imported into the neuron and to feed oxidative metabolism 
in neurons (Ide et al 2000). Under these conditions one can 
hypothesize nonparallel variations of CMR02 and CMRglc. 
If CBF is a robust index of NA, it might be tightly coupled 
to both, metabolism and NA, and might thus not vary alone 
while the two other parameters are stable (Magistretti 2000; 
Schaller et al 2004b). However, experimental data sug-
gest a situation of uncoupling between CBF and, at least, 
metabolism under pharmacologically induced conditions 
indicating that the involvement of neuron-derived nitric 
oxide (NO) in coupling ﬂ  ow to somatosensory activation 
is region-dependent, and that under nNOS inhibition, CBF 
and CMRglc may vary independently during NA (Dauphin 
et al 1995); therefore lactate, rather than glucose, may be 
the preferred fuel for neuronal metabolism (Slosman et al 
2001). However, the large carbohydrate uptake by the brain 
during recovery from maximal activation suggests that brain 
glycogen metabolism is important in the transition form rest 
to exercise, since this would explain the signiﬁ  cant post-
activity decrease in the O2/carbohydrate uptake ratio (Ide et al 
1999). Therefore, circulating lactate is used by the brain at 
euglycemia, with sparing glucose (Slosman et al 2001).
The neurogenic regulation of coupling 
by acetylcholine
Ach is a potent vasodilator innervating local cortical nitroxi-
dergic interneurons, cerebral capillaries and microarterioles 
(Herholz et al 2004). Cholinergic innervation mostly origi-
nates from the nucleus basalis of Meynert (Mesulam et al 
1983). The existence of such innervations, associated with 
the presence of cerebrovascular muscarinic receptors, has 
allowed to propose the implication of an ascending cholin-
ergic system in the regulation of cortical CBF (Dauphin et al 
1995). If cholinergic innervation is necessary to maintain 
CBF control in speciﬁ  c brain regions, degeneration of basal 
forebrain cholinergic neurons, as in AD, could therefore 
uncouple NA from CBF (or alter the nature of the cou-
pling) locally as well as in speciﬁ  c remote regions (Honer 
et al 1988; Blin et al 1994). Altered CBF response in such 
speciﬁ  c brain regions could not directly be interpreted as 
altered NA (Herholz et al 2004; Rosengarten et al 2006). 
One may hypothesize for these reasons that up-regulation 
of eNOS directly augments the neuron to vascular com-
munication or that the increased levels of vasorelaxing NO 
only improve the endothelial site of the coupling resulting 
in a better responsiveness (Rosengarten et al 2006). The 
clinical ﬁ  nding of pharmacological effect of acetylcholine 
esterase (AchE) inhibition in patients suffering from a vas-
cular related dementia may support the latter notion (Pratt 
et al 2002). Moreover, the nonuniform cholinergic cortical 
innervation could explain the regional variability in NVC in 
certain circumstances (Herholz et al 2004).
AchE inhibitor physiostigmine has been found to 
increase basal CBF and to decrease CMRglc, leaving CMRO2 
unchanged (Schaller 2005). Conversely, decreased CBF and 
increased CMRglc, a phenomenon that also illustrates a situa-
tion of uncoupling, follows systemic injection of the musca-
rinic antagonist scopolamine to humans or animals (Hof and 
Morrison 2004). Seigneur and colleagues (2006) suggest that 
the response to cholinergic activation may therefore result 
from the balance between the direct hyperpolarizing action 
of ACh and the depolarizing modulation of glutamate from 
the neighboring neurons, in addition to the modulation of 
the interglial communication pathway and/or the ionic traf-
ﬁ  c across blood vessels. In addition, during somatosensory 
activation, increased CBF has been found to be abolished 
by pharmacological intervention (eg, by scopolamine or by Neuropsychiatric Disease and Treatment 2008:4(3) 590
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bromopyruvate) such as inhibitors of ACh synthesis, and to 
be restored by physiostigmine (Tsukada et al 2000). Again, 
the neuronal response under pharmacological manipulation 
in these experimental studies is not measured through elec-
trophysiological recordings but assumed by the preservation 
of the metabolic response (Tsukada et al 2000). Therefore, 
one cannot conclude on an uncoupling between CBF and NA 
but only between CBF and cerebral metabolism under these 
conditions until all three parameters have been measured.
AchE activity in cerebral cortex is mainly due to the 
expression of this enzyme in cholinergic neurons and their 
axons (Herholz et al 2000). Intrinsic cholinergic neurons of 
the basal cortical pathway participate physiologically in the 
regulation of CBF responses (Tsukada et al 2000). Indeed, 
the direct stimulation of the substantia innominata or the 
nucleus basalis of Meynert elicits an increased cortical CBF 
that is not associated to a parallel change in CMRglc (Vaucher 
et al 1997) being hypothesized to be implicated in the brain 
parenchyma during NA, suggesting that AchE modulates 
glial activation and CBF. In addition, nucleus basalis of 
Meynert lesion studies in animal-models demonstrated 
to decrease cortical CBF (Peruzzi et al 1993). In contrast, 
it has been shown that lesions of the nucleus basalis of 
Meynert do result in an unexpected preservation of CMRglc 
associated to an increase in the density of GLUT3 (glucose 
transporter 3) glucose transporters in the cortex (Simpson 
et al 1994). This could be of great importance in pathologi-
cal situations, where the cholinergic system is supposed to 
be degenerated as, for example, in degenerative dementia 
with consecutive loss of cholinergic neurons located in 
basal ganglia, particularly in the nucleus basalis of Meynert 
(Herholz et al 2000). As the ascending cholinergic system 
appears to be involved in the neurogenic regulation of CBF 
and/or CMRglc, interestingly, ACh has been demonstrated 
to interact also with a local, nitroxidergic, and metabolic 
regulation (Herholz et al 2000).
The local regulation of coupling 
by nitric oxide
NO, ﬁ  rst discovered as the “endothelial-derived-relaxing-
factor”, is supposed to be implicated both in the regula-
tion of neuronal activity, CBF, and metabolic adjustments 
(Furchgott et al 1980). NO is synthesized by three isoforms 
of NOS and has been localized next to the cerebral vessels, 
within nervous ﬁ  bers suggesting a direct effect of NO on the 
CVsystem (Baumach et al 2004) and nNOS inhibitors allow 
demonstrating reductions in resting CBF as well as in CBF 
responses to somatosensory activation (Lindauer et al 1996). 
Moreover, nNOS inhibitors failed to modify either the CMRglc 
response or NA as assessed by somatosensory EP (Cruz et al 
2002) supporting the existence of independent mechanism 
for the regulation of CBF and cerebral metabolism (Lindauer 
et al 1996). Although NO participation in NVC is widely 
accepted, its exact mechanism of action remains yet unclear 
(Smith et al 2003). Since NO serves as a retrograde messen-
ger in synapses, one source of NO could be a leakage from 
synaptic clefts and rapid diffusion from active synapses to 
arterioles (Longstreth et al 1996). As capillaries are much 
closer to pyramidal neurons than arterioles, diffusion might 
be adequate to provide the pyramidal neurons with nutrients 
from capillaries, but ineffective in delivering metabolic mes-
sages to the CBF gate at the terminal arteriole (Schaller et al 
2004b) (Figure 3). Alternatively, NO could be produced by 
specialized periarteriolar neurons that are activated by direct 
stimulation from collateral axons, or by leaked neurotrans-
mitters form active synapses (Waldmann et al 2003). In 
support of this notion, NOS containing neurons are located 
close to pyramidal cells and vary in density consistent with 
the variation of microvasculature density (Togo et al 2004). 
In addition, a network of ﬁ  ne ﬁ  bers and staining for NOS 
is found around arterioles, suggesting that NOS-containing 
terminals provide a link between active pyramidal cells and 
relatively remote terminal arterioles (Togo et al 2004). NO 
is continuously released by endothelial cells into the vas-
cular system; but advanced age followed by the presence 
of vascular risk factor causes a decreased CBF, involving 
microvasculopathy with impaired NO release, which in turn 
results in regional metabolic dysfunction (Togo et al 2004). 
Figure 3 Neurovascular coupling mechanisms during cerebral somatosensory activity.Neuropsychiatric Disease and Treatment 2008:4(3) 591
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Whether the control of CBF by NO is implemented through 
simple diffusion or through specialized networks (neuronal 
or glial) should determine the degree to which the activity 
of clusters of neurons will produce similar amplitudes and 
temporal proﬁ  les of CBF changes (Atochin et al 2003) that 
can be visualized in FIT (Jagust 2005). Another factor in 
this complex equation is the nonuniform distribution of 
NO-producing neurons in different cortical areas (see for 
example Schaller 2004a). However, these ﬁ  ndings suggest 
that vascular pathology plays a crucial role in the pathogen-
esis of so-called neurodegenerative dementias (Zlokovic 
2005). Inﬂ  ammatory responses are commonly found in 
the brain under a variety of neurodegenerative dementias, 
including AD and DLB, in which up-regulation of NOS 
expression, suggesting overproduction of NO, is found in 
neurons and glia (Togo et al 2004). NO is thought to be 
involved in such neuroinﬂ  ammation due to its free radical 
qualities, which compromise cellular integrity and viability 
via mitochondrial damage (Togo et al 2004; Schaller 2007; 
Schaller et al 2007).
It is also not known whether NO is a direct mediator 
of enhanced CBF or has only a modulatory (“permis-
sive”) role. It remains unclear whether NO determines 
the vascular response quantitatively, or it is necessary 
for other mediators to exert their effect (Lindauer et al 
1996). In the rat cerebellum, decreased CBF response 
leads to inhibition of NO indiscriminately, indicating 
that NO acts as a direct mediator of local CBF control 
(Lin et al 2005). In contrast, in the rat somatosensory 
cortex NO has a modulatory effect, since the application 
of NO restored the CBF response after inhibition of NOS 
(Cholet et al 1997) suggesting that NVC processes might 
vary across the brain.
Although no study has addressed the effect of nNOS 
inhibitors on the physiological parameters of interest in the 
same model, all these data taken together suggest dissocia-
tion between vascular and metabolic/electrophysiological 
responses under nNOS inhibition (Gotoh et al 2001) as 
underlined by the use of knockout mice lacking the genes 
for either eNOS or nNOS (Ayata et al 1996; Browne et al 
1999). Pharmacological manipulation of NO through the 
blockade of its synthesis allows demonstrating region-
speciﬁ  c-effects; indeed, while cortical CBF response to 
cerebral nNOS inhibitors decreases activation, the vascular 
response is not altered in the thalamus (Cholet et al 1997) 
suggesting the existence of a complex mechanism in which 
the involvement of NO in coupling differs form one region 
to another.
Altered cerebrovascular dynamics 
in physiological aging
The vascular pathology seen in physiological aging process 
can be clinically silent or can lead to vascular compromise 
resulting in cerebral ischemia or even stroke representing 
probably the basis for alterations in NVC (Hock et al 1995; 
Terborg 2000). However, cerebrovascular risk factors may 
cause asymptomatic brain injury, strengthen the genetic risk 
with AD and possibly accelerate neurodegeneration-related 
processes (Decarli et al 2004) suggesting that these two 
diseases may act cumulatively or synergistically to cause 
clinical dementia (Decarli et al 2004).
Ultrastructure of the cerebral vasculature
The compromise to the ultrastructural integrity of the cere-
bral vasculature in physiological aging process is mainly the 
result of arteriosclerotic changes, ﬁ  brohyaline thickening of 
the vessel wall, necrosis of smooth muscle cells and thick-
ening of the basement membrane, that gradually increase 
with age (Masawa et al 1994; Hock et al 1995). Although 
sclerotic changes correlate with the degree of hypertension, 
age seems to be an independent risk factor (Masawa et al 
1994). These morphological changes decrease the elasticity 
and compliancy of affected vessels, which include capil-
laries, larger arterioles and cerebral arteries (Kacem et al 
1998). Venous alterations that accompany aging, known as 
periventricular venous collagenosis, are also found in about 
65% of the population over 60 years old, and can occlude 
veins completely in severe cases (Moody et al 1997). There 
is also an increase in the tortuosity of some vessels with 
physiological aging, most notably in the arteriovenous-
capillary bed, as well as changes in the density of capillaries 
and arterioles, but this effect have not yet been observed in 
venules (Hock et al 1995).
Resting cerebral blood ﬂ  ow
Aging is associated with a rarefaction of the microvascu-
lature followed by a signiﬁ  cant decrease in resting CBF in 
the cortical and subcortical parenchyma reducing metabolic 
support for neuronal signaling particularly when levels of 
neuronal activity are high (De la Torre et al 1992; Postiglione 
et al 1993; Reiman et al 2004). Using positron emission 
tomography (PET), CMRO2 demonstrates a significant 
decline during physiological aging process predominantly 
at the left superior temporal cortex and more marked in 
the association cortices of the left hemisphere (Postiglione 
et al 1993; Reiman et al 2004). Evidence that age-related 
declines in CBF are not speciﬁ  c for neuronal function is Neuropsychiatric Disease and Treatment 2008:4(3) 592
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provided by the demonstration that aging decreases both 
basal CBF and the increase of CBF normally accompanying 
neuronal stimulation (Reiman et al 2004). However, consid-
ering the signiﬁ  cance of age-related changes in CBF and/or 
metabolism, two caveats exist: (i) aging-related cerebral 
atrophy may confound the interpretation of imaging studies 
of CBF (Giovacchini et al 2004); and (ii) a decreased local 
CBF in the aged brain could be a secondary rather than a 
primary factor of a decline in neural function, especially in 
the grey matter (Illes et al 2004). However, there has been 
discussion as to whether neuronal loss subtending gross 
structural changes in aged healthy volunteers fully explains 
the regional changes measured with functional imaging (van 
Laere et al 2001). Contrary to the widely belief, neuronal 
concentration remains essentially constant during normal 
aging process, but neuron size decreases – presumably as a 
result of reduced dendritic arborization and dendritic spine 
concentration (Anderson et al 1996) – and the number of glial 
cells decreases (Baron et al 2000) occuring with substantial 
variability (van Laere et al 2001).
Vascular reactivity
Speciﬁ  c, age-associated decrease in the vascular reactivity of 
cerebral vessels to various chemical modulators, including 
carbon dioxide (CO2) is seen (Bakker et al 2004). Gener-
ally accepted, increased blood CO2 results in dilatation of 
cerebral arterioles under physiological conditions (Venton 
et al 2003). Decreased vascular reactivity to hypercapnia has 
been observed in aged animals or humans with and without 
risk factors for arteriosclerosis (Wolfson et al 1985). In PET 
of rCBF, a signiﬁ  cant decrease in a total vascular response 
from a hypocapnic to a hypercapnic state is observed in 
older individuals as compared to younger ones (Mufson et al 
2003; Reiman et al 2004). In aged animals, there is a reduced 
degree of vasodilatation in response to cerebrospinal ﬂ  uid 
perfusion of the vasodilators adenosine, ACh and bradykinin 
(Mayahn et al 1990).
The exact mechanism of age-related changes in vascular 
reactivity have not been elucidated, although it has often been 
suggested that aging-related effects may be most signiﬁ  cant 
for agents that act by modulating the release of endothelium-
derived relaxing factor (NO) (Riecker et al 2003; Rodrigo 
et al 2004; Ranicillac et al 2006). But, the wall of the cere-
bral arterioles undergoes atrophy during aging and there is 
a decrease in the distensibility of the cerebral vessels, which 
is mainly based on alterations of their composition with a 
disproportionate reduction of the distensible elements (Hajdu 
et al 1990). Therefore, cerebral vessels in older subjects may 
not react as effectively in response to dilator stimuli such 
as hypercapnia or those released during neuronal activation 
(Riecker et al 2003). In addition to such structural changes, 
mechanisms that might affect vascular reactivity independent 
from NA include the gliosis that accompanies tissue scarring 
from damaged brain tissue, and the disruption of long-range 
aminergic and cholinergic ﬁ  bers that innervate the vascula-
ture (Czosnyka et al 2004). Thus, altered NVC can occur 
close to a damaged brain region even in apparently normal 
tissue (Back et al 1998). Moreover, age-related changes in 
vascular reactivity might vary across brain regions (Hund-
Georgiadis et al 2003). A study that compared the resting 
and stimulus-evoked increases in CBF ipsilateral in both 
the parietal and frontal cortex of young rats demonstrated 
altered effects in the frontal cortex of aged rats (Ranicillac 
et al 2003). This ﬁ  nding suggests that the structural and 
functional changes that occur in vessels during physiologi-
cal aging cause disability of cerebral microvessels to deliver 
nutrients and oxygen to the brain optimally, thereby affecting 
the mitochondrial ability to respond to anoxia (Mufson et al 
2003) mirroring the nonuniform distribution of arterioscle-
rosis in the brain (see for example Paul et al 2005).
There is an age-related dissociation of calbindin and the 
glutamate receptor GluR2 within cholinergic basal forebrain 
neurons, implying that these molecules act synergistically 
to induce excitotoxic cell death during aging, and possibly 
during AD (Mufson et al 2003). Choline acetyltransferase 
(ChAT) activity and cholinergic basal forebrain neuron num-
ber are preserved in the cholinergic basocortical system and 
up-regulated in the septohippocampal system during early 
as compared with end-stage AD (Mufson et al 2003). In 
contrast, the number of cholinergic basal forebrain neurons 
containing nerve growth factor (NGF) receptors is reduced 
early in the disease suggesting a phenotypic silence and not 
a frank loss of neurons (Mufson et al 2003). In end-stage 
AD, there is a selective reduction in trkA mRNA but not 
p75(NTR) in single cholinergic basal forebrain cells sug-
gesting a neurotrophic defect throughout the progression of 
AD (Mufson et al 2003; Zlokovic 2005) and indicating that 
multiple factors may play different roles in the consecutive 
dysfunction in aging and AD (Mufson et al 2003).
Additional signiﬁ  cance of aging-related 
changes in vascular plasticity
Aging-related changes in the vasculature also inﬂ  uence other 
critical aspects of neural function and plasticity (Mark et al 
1997). The microvasculature is critically involved in regulat-
ing adult neurogenesis, as a source of local and blood-borne Neuropsychiatric Disease and Treatment 2008:4(3) 593
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factors providing an appropriate environment for neuro-
genesis stimulating the proliferation and differentiation of 
progenitor cells (Schaller 2004a). For this reason, the role in 
brain repair after ischemic events is under discussion: The 
production of new granule neurons in the subgranular zone 
of the adult dentate gyrus occurs within “neuroangiogenic 
foci” where neuronal, glial and endothelial precursors are 
divided into tight clusters (Schaller 2004a; Togo et al 2004). 
This association between endothelial and neuronal prolifera-
tion in the subgranular zone suggests that signals originating 
from somatic tissues or from the CNS act simultaneously to 
stimulate neurogenesis and angiogenesis, or that the initiat-
ing signal activates proliferation of only one cell type, which 
then stimulates proliferation of the other (Schaller 2004a). 
In addition to trophic factors, endocrine growth factors 
like insulin-like growth factor (IGF-1) inﬂ  uence neuronal 
turnover in the adult brain, regulating neurogenesis, and the 
decline in neuronal turnover during advanced aging may be 
the result of decreased IGF-1 levels (Sokoloff, 1981).
Pathological-induced alterations 
of cerebral blood ﬂ  ow and/or 
metabolism regulation
Cerebral blood ﬂ  ow
The collective ﬁ  ndings discussed so far suggest that brain 
hypoperfusion precedes the hypometabolic and neurodegen-
erative changes (Ruitenberg et al 2005), investigating early 
stages of dementia in which advanced neurodegeneration 
have not yet evolved. In the opposite sequence, neurons 
exposed to oxidative stress and impaired energy substrate 
delivery would further reduce CBF to accelerate neuronal 
death, a mechanism inconsistent with cellular survival 
(Zlokovic 2005). The use of cerebral metabolism as an 
index of NA may not always be valid, particularly when 
the biochemical steps related to cellular energy and cell-
membrane turnover is altered like in AD (Silverman et al 
2005). Therefore adequate measurement methods of NA 
would be needed to examine the preservation or alteration of 
NVC in these pathological states: in these selected situations, 
CBF variations appear to be non reliable indices of cerebral 
metabolism and, putatively, of neuronal activity (Gsell et al 
2000). This may limit the use of activation IT in patho-
physiological conditions (Magistretti et al 1999). Another 
major problem is represented by the yet unknown coupling 
between oxidative metabolism and CBF: Techniques such as 
fMRI and near infrared spectroscopy (NIRS), that record a 
complex signal linked both to variations of CMR02 and CBF, 
might thus fail to distinguish between these two parameters 
(Gesell et al 2000).
Specific pattern of reduced CBF and metabolism 
have been demonstrated for several subtypes of dementia 
(Silvermann et al 2004). For a number of authors, decrease 
of CBF and glycolytic metabolism are tightly correlated 
to the severity of the disease (Jobst et al 1992; Pietrini 
et al 2000). Alterations of CBF and cerebral metabolism 
have been presented over the years as parallel events that 
should directly reﬂ  ect the local loss of neurons and, in turn, 
the decrease in the local metabolic demand (Frachowiak 
et al 1981). However, uncoupled variations of resting 
CBF and metabolism exist in AD (Nagata et al 1997). In 
fact, a slight increase in CMRO2, suggesting a so called 
“misery perfusion”, has been found in some brain regions 
of AD (Nagata et al 1997). Moreover, behavioral activa-
tion and CMRglc measurements by PET suggest that the 
regional hypometabolism found in AD is not the result of 
neurodegeneration, but appears to precede it (De la Torre 
et al 2002).
Though neuronal loss alone cannot explain the cerebro-
vascular and metabolic alterations observed in AD, the patho-
physiological mechanisms, which alter CBF and/or local 
metabolism, are still unknown (Nixa et al 2002; Iadecola et al 
2003), but it seems that this phenomenon may be an early 
event in the pathogenesis of AD. Different working hypoth-
eses have recently been suggested, stressing the importance 
of alterations of the ascending cholinergic pathway and 
of endothelial functions as well as of pathophysiological 
perturbations associated with β-amyloid protein (AP) over-
expression (Poirier et al 2000). It is thus quite tempting 
to propose that two of the most common neuropathologic 
landmarks of AD, namely, cholinergic dysfunction and AP 
deposition, may in fact depend on the integrity of local lipid 
homeostatic processes, which in turn are strongly dependent 
upon proper lipid delivery by the apoE transport system 
(Poirier et al 2000).
The argument that hypometabolism in AD may elicit 
microvascular changes at some point is not supported by 
a considerable number of animal experiments. But chronic 
cerebral hypoperfusion can trigger oxidative stress, energy 
metabolic deﬁ  cits, and memory loss before any neuronal 
structural pathology materializes (Chen et al 2005; Sun 
et al 2005), whereas there are no data that we are aware of 
that indicate the reverse process can or does occur. More-
over, the recent discovery of “neuroglobin” in rodent and 
human brain could partly explain why CA1 hippocampal 
neurons are exquisitely sensitive to hypoperfusion leading Neuropsychiatric Disease and Treatment 2008:4(3) 594
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to hypometabolism (Chen et al 2005; Sun et al 2005). 
Neuroglobin in brain appears to act much like myoglobin 
in cardiac muscle cells; it aids oxygen diffusion to the mito-
chondria (Chen et al 2005). Decreased tolerance of CA1 to 
ischemia may be due to lower oxygen supply resulting from 
less available neuroglobin, whose lowest expression is in 
the hippocampus (Chen et al 2005). Consequently, brain 
hypoperfusion could reduce neuroglobin levels in CA1 and 
initiate mitochondrial oxidative stress (Chen et al 2005).
Cholinergic pathways
Cholinergic pathways projecting from basal forebrain 
regions to the hippocampus and neocortex are believed to 
play an important role in learning and memory processes 
(Bartus et al 1982). In patients with AD, the cholinergic sys-
tem of the basal forebrain, including the areas of projection, 
is disrupted and/or altered (Collerton 1986). Moreover, as 
direct stimulation of the nucleus basalis of Meynert induces 
a major increase in CBF in the cortex without variation 
of the glucose metabolism, thus suggesting a preferential 
regulation of CBF by this region (Barbelivien et al 1999). 
Interestingly, a reduction in the density of the muscarinic 
receptors within cerebrovascular bed has been reported in 
AD, a situation that, associated to the parallel decrease in 
the density of contacts between cholinergic terminals and 
nitroxidergic cortical interneurons, could be responsible for 
an uncoupled state between CBF and cerebral metabolism 
(German et al 2003). Such a situation might be exacerbated 
by the alterations of the modulation of the cholinergic system 
of the nucleus basalis of Meynert, for example by galanin 
or GABA, known to modify the functional input of the 
cholingeric system onto CBF regulation (Barbelivien et al 
1999). These data indicate that the cortical neurodegenera-
tive changes occur before the deposition of AP (German 
et al 2003).
Glucose pathways
Glycolytic enzymes and glucose transporters present at the 
level of the blood–brain barrier (BBB) and neurons also 
appear to exhibit an abnormal function during AD (Kalaria 
et al 1989; Mielke et al 1996). In particular, a decrease in 
the density of GLUT1 and GLUT3 glucose transporters has 
been reported (Simpson et al 1994). Overall, these alterations 
should induce metabolic changes characterized by an impor-
tant decrease in CMRglc; since CMRO2 is supposed to be less 
decreased, this should elicit an increase in the CMRO2/CMRglc 
ratio, characteristic of a shift towards aerobic metabolism 
(Fukuyama et al 1996).
Amyloid-β
A number of in vivo neuroimaging techniques, which can 
reliably and noninvasively assess aspects of neuroanatomy, 
chemistry, physiology, and pathology, hold promise as 
biomarkers (Dickerson et al 2005): Apolipoprotein E4 
(apo E4) is a component of both the AP and the tangles of 
hyperphosphorylated tau that characterize AD (Mullan et al 
1993). Furthermore, in AD early accumulation of AP in 
several brain regions as well as in the vascular compartments 
has been demonstrated (Mullan et al 1993). Amyloid angi-
opathy induces a structural alteration of the vessel wall, an 
endothelium-dependent perturbation of the cerebrovascular 
reactivity and an increase in the BBB permeability (Blanc 
et al 1997) possibly leading to hemorrhage and ischemia 
(Koistinaho et al 2005). Moreover, intra-arteriorlar injection 
of AP reduces the internal diameter of vessels and thereby 
can decrease CBF and/or energetic supply to the cerebral 
parenchyma (Duara et al 1992). Accordingly, several studies 
of cerebral ischemia have shown similar alterations. Indeed, 
chronic hypoperfusion in the rat has been found to induce 
alterations of brain capillaries associated with an over-
expression of the AP precursor, changes in the function 
of glucose transporters, and dysfunction of the cholinergic 
system (Ishimaru et al 1998). Currently, different tools that 
enable direct, quantitative detection of AP deposits found 
in AD support the existence of an excellent biomarker 
for different imaging modalities and are part of current 
experimental research (Dickerson et al 2005).
Nitric oxide pathways
NOS is supposed to be the pivotal factor in the pathogenesis 
of different subtypes of dementia, especially AD (Lahiri et al 
2003; Rodrigo et al 2004) demonstrating (i) the release of 
NO from cerebral endothelial cells to produce vasodilata-
tion, a fairly well established reaction (Iadecola et al 2003); 
(ii) NO produced by eNOS to play a key role in vascular 
tone and blood pressure control, and to inhibit platelet and 
leukocyte adhesion to the endothelium, a process that may 
down-regulate proinﬂ  ammatory events (Iadecola et al 2003); 
(iii) the stimulation angiogenesis via vascular endothelial 
growth factor reduces shear stress on the vessel wall and, 
consequently, protects endothelial cell function (Lahiri et al 
2003). NOS dysfunction may therefore disrupt the delicate 
balance between the brain’s energy requirements and blood 
supply, and render the brain more vulnerable to (ischemic) 
injury (Iadecola et al 2003).
NO had been shown to diffuse toward the lumen of blood 
vessels where it helps maintain CBF, by reducing blood Neuropsychiatric Disease and Treatment 2008:4(3) 595
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viscosity and resistance (Niwa et al 2002a). However, normal 
blood ﬂ  ow can be compromised through physical or chemical 
stimuli affecting eNOS levels localized in the endothelial 
cell caveolae (small invaginations in the plasma membrane 
of endothelial cells involved in cell signalling) (Hof et al 
2004; Iadecola 2004). Thus, deregulation of vascular NO 
production can occur from chronic cerebral hypoperfusion 
(Niwa et al 2002a, 2002b) as follows: chronic cerebral hypo-
perfusion below a critically attained threshold initiates eNOS 
activation and deregulation of NO release from the endothe-
lium in the hippocampus and endorhinal cortex, results in an 
increased vascular resistance or blood viscosity and causes 
micro-environmental hemorheological and hemodynamical 
disturbances (Niwa et al 2002b). This effect of altered mecha-
notransduction on eNOS activity up-regulates NO release in 
order to reset baseline values and diminish the molecular and 
cellular damage caused by hypoperfusion (Niwa et al 2002b; 
Iadecola 2004). In view of failure to achieve homeostasis, 
depletion of basal NO levels results in the incapability (i) to 
regulate normal vascular perfusion, (ii) to block granulocyte 
adhesion in blood vessels, (iii) to prevent proinﬂ  ammatory 
intraneuronal reactions, and (iv) to maintain endothelial cell 
conformation, resulting in endothelial cell shape distortions 
(Iadecola 2003). The latter phenomenon may explain base-
ment membrane thickening commonly found regionally in 
AD brain capillaries and potentially seen as a compensatory 
reaction to increased interendothelial distance created by NO 
deregulation (Niwa et al 2002b). Endothelial cell distortion 
would also permit mobilization of the powerful vasoconstric-
tor, endothelin-1, and impair GUT-1 activity, the molecule 
responsible for glucose transport into brain (Iadecola 2003). 
Thus, AP compromises the ability of cerebral endothelial 
cells to produce vascular relaxing factors, impairs the ability 
of cerebral blood vessels to maintain adequate ﬂ  ow dur-
ing hypotension, and attenuates increased CBF evoked by 
enhanced NA (Iadecola 2003).
NO appears to affect nuclear factor kappa beta (NF-κβ) 
directly, a nuclear transcription factor that is widely expressed 
in CNS and that is involved in the activation of several 
inﬂ  ammatory mediators (Howard et al 1998; Schaller et al 
2007). Simultaneously to NF-κβ activation, in most types 
of cells, inhibitor IκBα is phosphoryled and proteolytically 
degraded (Howard et al 1998; Camanduola et al 2000). 
After activation, free NF-κβ dimers are translocated 
into the nucleus, bind to the promoter region of target 
genes and induce the transcription required for DNA 
binding and protein dimerization (Howard et al 1998). 
However, a TNF-α-induced NF-κβ-activation mediates 
the expression of adhesion molecules on the endothelial 
surface. NO inhibits NF-κβ transcriptional activation in a 
variety of cells, including monocytes and endothelial cells 
(Howard et al 1998). When NO is activated by TNF-α, the 
NF-κβ inhibitor, inhibitor of NF-kappaBalpha (IκBα), is 
no longer stabilized and inﬂ  ammatory cytokines, such as 
interleukin-1 and interleukin-6, are activated in the brain 
(Howard et al 1998; Camanduola et al 2000). Structural 
microvessel pathology, which is frequently observed in AD 
brains, results in basement membrane thickening, buckling 
of the lumen, and distortion of the endothelium (Zhen et al 
1991). Such histopathological changes will alter normal NO 
release from the endothelium, allowing IκBα degradation 
and thereby preventing proinﬂ  ammatory downregulation via 
inhibition of NF-κβ (Howard et al 1998). Thus, it is possible 
that endovascular NO, derived from eNOS, may inhibit 
NF-κβ tonically under nonstimulated conditions (Iadecola 
2004). However, during advanced physiological aging, 
enhanced by vascular risk factors reducing cerebral perfusion 
further, this mechanism may be lost, increasing the sensitivity 
to NF-κβ-activation (Howard et al 1998). In agreement with 
the hypothesis connecting vascular NO levels with AD is 
the ﬁ  nding that in the presence of NO donors, TNF-α fails 
to stimulate NF-κβ released from endothelial cells, allowing 
NO to stabilize the NF-κβ inhibitor, IκBα, and to prevent its 
degradation (Howard et al 1998). The binding of NF-κβ to the 
NF-κβ binding site in the inducible NOS promoter plays a 
crucial role in the transcriptional regulation of the inducible 
NOS gene (Howard et al 1998). Furthermore, NO donors can 
directly inhibit the DNA binding activity of NF-κβ (Howard 
et al 1998). Brieﬂ  y, NO derived from eNOS has the ability 
to downregulate proinflammatory events by inhibiting 
NF-κβ activation of proinﬂ  ammatory cytokines leading to 
microglial activation and neuronal damage (Ho et al 2005).
Neurovascular hypothesis
Neurovascular uncoupling suggests various neurovascular 
related pathogenic mechanisms for the origin of AD (Iadecola 
2004). Faulty clearance of AP across the BBB by aberrant 
angiogenesis or endothelial aging process could lead to for-
mation of vascular amyloid lesions (Figure 4) (Zheng et al 
1991). Inefﬁ  cient AP proteolysis ampliﬁ  es insufﬁ  cient AP 
BBB clearance, whereas AP vascular accumulations stimu-
late proteasome-dependent degradation of the lipoprotein 
receptor-related protein (LRP) clearance receptor and is 
antiangiogenic (Zheng et al 1991).
As suggested by Zlokovic (2005), premature cerebrovas-
cular senescence owing to atherosclerosis, cerebral amyloid Neuropsychiatric Disease and Treatment 2008:4(3) 596
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angiopathy and/or elevated soluble AP concentration can 
result in loss of endothelium-dependent CBF regulation, 
in neurovascular uncoupling, and in brain hypoperfusion 
(Zheng et al 1991). Islets of regressed and degenerated 
microvessels consequent to aberrant angiogenesis could 
act as seeds for the dense-core amyloid plaques and might 
activate the neuroinﬂ  ammatory response (Zheng et al 1991), 
but our understanding of the mechanisms by which vascular 
dysregulation alters brain function is still rudimentary.
The state-of-the-art-imaging
Biological dementia process begins years before it is diag-
nosed clinically (Mosconi et al 2005) (Figure 5). The optimal 
time to initiate a neuroprotective, therapeutic step is during 
the preclinical period of the disease, when neuronal degenera-
tion has begun, but cellular and biochemical damage is not 
yet sufﬁ  cient for symptoms to manifest (Mathis et al 2005). 
The ability to identify this preclinical state is currently very 
limited (Iadecola 2004; Chong et al 2005). The most useful 
strategy is to identify “at risk” subgroups and to search for 
preclinical neurodegeneration in these enriched populations 
(Zheng et al 1991). The promise of achieving diagnostic 
speciﬁ  city through neuroimaging lies with the potential iden-
tiﬁ  cation of pathognomonic proteins (Mathis et al 2005).
Recent advances in imaging AP, one of the hallmarks of 
AD, offer such a technological breakthrough and the possi-
bility for more efﬁ  cient assessment of antiamyloid interven-
tions as well as speciﬁ  c noninvasive diagnostic capabilities 
(Mathis et al 2005).
Structural imaging
Clinical symptoms of AD result from synaptic dysfunction 
that may be associated with or precedes neuronal loss, 
although the underlying mechanisms are unknown (Snyder 
et al 2005). Neuropathological studies have implicated the 
gray matter of the medial temporal lobe as an early site 
of pathological involvement in AD (consistent with the 
characteristic amnesic presentation in this disorder), and 
many IT have therefore focused on this part of the brain 
(Alexander et al 1995; Paris 1997). MRI enabled the visu-
alization of speciﬁ  c structures within the medial temporal 
lobe, such as the hippocampus itself, the parahippocampal 
gyrus, subiculum, entorhinal cortex, and amygdale (Chong 
et al 2005) with good clinical correlations to dementia 
(Earnest et al 1954).
The future focus of high-resolution structural MRI on 
these areas that are affected earliest in AD (ie, entorhinal 
cortex and hippocampus) may increase diagnostic preci-
sion (Chong et al 2005). With the ability to acquire rapidly 
high-contrast, high-spatial-resolution, three-dimensional 
IT (Magistretti 2000; Thompson et al 2004), sophisticated 
brain-mapping algorithms identify complex, shifting patterns 
of brain structural deﬁ  cits, revealing where, and at what 
rate, the path of brain deterioration in illness deviates from 
normal (Csernansky et al 2005). Results vary, depending 
in part on the speciﬁ  c measurement approaches (eg, volu-
metric, planimetric, linear), and many investigations suffer 
from limitations similar to those described for the qualita-
tive mesiotemporal atrophy study (Poulin et al 2002). The 
measures of the temporal cortices, including the amygdala, 
hippocampus, and inferior temporal lobes, along with the 
anterior cingulate cortex, associated with the largest mag-
nitudes of effects, and, hence, these could serve as the most 
useful structures to help clinicians differentiate AD from 
physiological aging (Poulin et al 2002).
Cerebrovascular disease
Silent cerebrovascular brain damage is associated with 
diminished cognitive performance in older people (Hock et al 
1995) suggesting that CVD is associated with increased risk 
of mild cognitive impairment and of conversion to dementia 
(Ross et al 2005). In addition, the presence of CVD may 
inﬂ  uence clinical presentation and neurobiology of AD and 
seem to contribute to determine cognitive impairment in an 
additive fashion (Ross et al 2005), suggesting that cogni-
tive impairment in stroke patients may be related to cortical 
neuronal dysfunction rather than purely subcortical change 
(Mackowiak-Cordoliani et al 2005). Moreover, cortical 
regions not obviously infarcted may have dysfunctional 
neurons, the pathophysiological basis for which needs further 
study (Ross et al 2005).
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Figure 4 Neurovascular mechanism of Alzheimer’s disease. (Zlokovic 2005).
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Cholinergic deficits in VaD are due to ischemia of 
basal forebrain nuclei and of cholinergic pathways and 
can be treated with the use of the AchE inhibitors used in 
AD (Erkinjunttti et al 2004). Since the response in AD to 
AchE inhibitors might differ according to the magnitude of 
the cerebrovascular contribution, estimating the vascular 
burden might also help to understand the variability of the 
response of AD patients to drug treatment (Erkinjunttti et al 
2004). For isolated subcortical CVD, a particular clini-
cal picture does not characterize its association with AD, 
and the additional diagnostic potential of IT is huge again 
(Jellinger 2005). Knowledge is lacking in determining the 
contribution of subcortical CVD to cognitive impairment 
alone or in addition to AD (Honig et al 2005). Notably, 
the impact of number, size and type of lesions on cognitive 
impairment is unclear (Honig et al 2005). A recent ﬁ  nding 
supporting this hypothesis is that corpus callosum atrophy – a 
proxy of global axonal loss – is strongly associated with 
cognitive impairment independently of any effect of white 
matter lesions depicted on T2 weighted MRI (Pantel et al 
1998). Moreover, lacunes and other white matter lesions 
may have different impacts on cognitive impairment, as the 
ﬁ  rst consists pathophysiologically of complete interruption 
of axonal ﬁ  bers on pathology, whereas the second is related 
to incomplete infarction and demyelination (Lazarus et al 
2005). Lastly, not all white matter changes detected by imag-
ing techniques are alike (Lazarus et al 2005). Patchy areas 
of hypodensity in the white matter on CT and irregular and 
conﬂ  uent white matter hyperintensities on MRI have been 
suggested to be due to ischemia, whereas other types of 
hyperintensities seem to be related more often to nonischemic 
changes (Lazarus et al 2005). Punctuate lesions can be an 
early stage of conﬂ  uent lesions, but sometimes there seems 
to be no pathological substrate (Lazarus et al 2005). Diffuse 
and homogenous periventricular hypodensity of the white 
matter on CT and smooth periventricular hyperintensities on 
MRI are due to an increased water content, demyelination, 
and subependymal gliosis caused by nonischemic alterations 
Figure 5 Evolution of sporadic Alzheimer’s disease in view of aging and vascular risk factor.
Abbreviation: APP, amyloid precursor protein.
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of the periventricular ﬂ  uid dynamics (Lazarus et al 2005). 
It was found that diffusion anisotropy which correlates with 
the apparent diffusion coefﬁ  cient (ADC) mapping in MRI, 
did reﬂ  ect mental ability and was reﬂ  ected by physiologi-
cal aging when a series of measurements was performed in 
the centrum semiovale – a brain region that at least in part 
contains watershed areas (Lövblad et al 2004). However, the 
altered fractional anisotrpy and ADC values in the genu of 
the corpus callosum of AD patients presumably reﬂ  ect the 
microscopic changes of white matter degeneration in AD 
and vary with disease severity (Kantarci et al 2002; Lövblad 
et al 2004).
While diffusion-weighted MR imaging (DWI) is used 
primarily for the investigation of stroke by using the strong 
sensitivity to ischemia (Kantarci et al 2002; Lövblad et al 
2004), the ADC maps that can be generated from the same 
image sets seem to contain further information regarding 
tissular pathophysiology: indeed this has been demonstrated 
in both animal and now in human models of stroke where 
the ADC seems not just to reﬂ  ect the presence or absence of 
a lesion but to correlate with the underlying hemodynamic 
pathophysiology (Lövblad et al 2004). The changes associ-
ated with AD are particularly interesting because diffusion 
tensor imaging (DTI) within the white matter may be abnor-
mal in the early stages of AD and has the potential to monitor 
the course of the disease (Muller et al 2005). Such MRI can 
give information very similar to that obtained by SPECT and 
PET to detect cortical atrophy and are very sensitive early 
indicators of hippocampal dysfunction (Yamamoto et al 
1980; Muller et al 2005). The combination of macro- and 
microstructural imaging parameters areas could therefore be 
promising in early detection of neurodegenerative processes 
(Muller et al 2005). The main potential advantages of DWI 
over SPECT or PET include that this IT does not use radioac-
tive isotopes, has superior spatial resolution and can be done 
in a single session with structural MRI, thereby reducing total 
examination time in detecting the water diffusivity caused by 
neuropathological change in AD and vascular dementia.
Differentiating Alzheimer’s disease from other forms 
of degenerative dementia
Some infrequent types of dementia have a relatively speciﬁ  c 
imaging pattern and, in conjunction with typical clinical 
ﬁ  ndings, can be easily distinguished from AD approaching 
the accuracy of neuropathology (Chong et al 2005). The mor-
phological pattern perhaps most speciﬁ  c is that of extremely 
severe frontopolar and temporopolar atrophy of the cortical 
layer and white matter association of the frontal (ballooning) 
and temporal horns (Chetelat et al 2005). Recent advances 
in imaging AP, one of the hallmarks of AD, offer a techno-
logical breakthrough and the possibility for more efﬁ  cient 
assessment of antiamyloid interventions as well as speciﬁ  c 
noninvasive diagnostic capabilities (Mathis et al 2005).
DWI-MRI is sensitive to microscopic motion of water 
molecules in cerebral tissue (Lövblad et al 2004). Its primary 
application has been in the diagnostic evaluation of acute 
cerebral ischemia (Lövblad et al 2004). The IT has also been 
applied to study patients with AD, postulating that pathological 
destruction of cell membranes, with subsequent loss of 
myelin and axonal processes due to Wallerian degeneration, 
increases the water diffusion in the hippocampus and afferent 
white matter tracts (Steffens et al 2003). Such pathological 
changes manifest by an increased apparent DWI; DTI enables 
measurement of directionality or asymmetry of microscopic 
water movement in tissue (Kantarci et al 2002, 2005; Lövblad 
et al 2004). Such asymmetric diffusion, known as anisotropy, 
is seen in normal white matter, since the integrity of white 
matter tracts that allows diffusion of water preferentially 
parallel, rather than perpendicular, to the tracts (Steffens et al 
2003). Recently, the IT has been applied in human studies 
of AD (Steffens et al 2003; Kantarci et al 2005) indicating 
that physiological aging without dementia is characterized 
by signiﬁ  cant changes in the white matter most prominently 
in anterior brain regions (Steffens et al 2003; Head et al 
2004). The dissociation between the regional effects of 
aging and dementia suggests that the mechanisms underly-
ing age-associated cognitive decline are distinct from those 
underlying AD dementia (Head et al 2004).
The mild increase in OEF seen in AD can be interpreted as 
evidence of participation of the vascular factors in the reduc-
tion of energy metabolism (Nagata et al 2002). Since vascular 
reactivity and vascular transit time were well preserved in 
AD, the mild increase of OEF is associated with vascular 
involvement possibly at the level of capillary and BBB, but 
not at the level of arterioles (Nagata et al 2002).
Magnetic resonance spectroscopy
Magnetic resonance spectroscopy (MRS) is an application 
of MRI that allows noninvasive assessment of a number of 
local metabolite in brain tissue (Lin et al 2005). The presence 
of altered membrane metabolism in AD creates opportunities 
for both phosphorus and proton MRS investigations of brain 
chemistry where conventional structural imaging appears 
normal (Kantarci et al 2002). Phosphorous MRS allows 
the simultaneous observation of a number of membrane 
phospholipid precursors and breakdown products; a loss of Neuropsychiatric Disease and Treatment 2008:4(3) 599
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membrane integrity would likely change the relative ratio of 
these compounds compared to their levels in healthy tissue 
(Valenzuela et al 2001; Leybaert 2005). Less robust evidence 
using phosphorous MRS has shown signiﬁ  cant phosphocre-
atine decline and increments in the cell membrane phospho-
monoesters in the early, and possibly asymptomatic, stages 
of the disease (Valenzuela et al 2001). Signiﬁ  cant relation-
ships between measured metabolites and cognitive indices in 
patients with mild cognitive impairment and AD have been 
reported (Chantal et al 2002). In addition, phosphodiester 
concentration has been found to correlate strongly with AD 
plaque counts (Leybaert 2005). MRS of AD has therefore 
introduced new pathophysiologic speculations (Valenzuela 
et al 2001). Studies of automated MRS for AD diagnosis 
have reported high sensitivity and moderate speciﬁ  city, but 
are yet to test prospective samples (Valenzuela et al 2001). 
As described earlier in this review, selective decreases in 
temporoparietal perfusion have also been associated with 
the diagnosis of AD using PET (Jagist 2001). Since cerebral 
metabolism is closely coupled to CBF, these brain regions 
might demonstrate altered bioenergetic indices, which could 
be detected using phosphorus MRS (Valenzuela et al 2001). 
In contrast to consistent ﬁ  ndings of the in vitro studies with 
respect to membrane biochemistry, the ﬁ  ndings in vivo are 
extremely variable for AD (Jones et al 2004): these studies 
suggest a possible role for MRS in early diagnosis and for 
surrogate biochemical markers for monitoring disease pro-
gression and therapeutic response.
Proton MRS allows in vivo assessment of different 
metabolites like N-acetylaspartate (NAA), glutamine and 
glutamate, GABA, myo-inositol (Ins), glycine, mobile cho-
line moieties, creatine (Cr) and phosphocreatine, lipids, and 
lactate (Heminghaus et al 2003). N-acetylaspartate is present 
primarily in neurons, but not in glial cells or other nonneuro-
nal tissue (Leybaert 2005). Although the exact metabolism 
of N-acetylaspartate remains unclear, N-acetylaspartate is 
generally thought to represent a marker of neuronal function 
(Leybaert 2005). The N-acetlyaspartate level is decreased in 
cases of neuronal loss or damage yet but may return to normal 
levels during recovery suggesting a possible re-synthesis of 
the N-acetylaspartate pool (Signoretti et al 2002). Elevated 
myo-inositol levels mark gliosis, membrane dysfunction, 
and/or cytoskeletal abnormalities (Heminghaus et al 2003). 
Elevated choline levels reflect cellular proliferation or 
myelin breakdown (Heminghaus et al 2003). In both vascular 
dementia and AD, ratios of NAA/Cr were decreased, which 
may be attributed to neuronal degeneration and loss. The Ins/
Cr-ratios were increased indicating either enhanced gliosis 
or alteration of the cerebral inositol metabolism (Huang et al 
2001; Signoretti et al 2002; Leybaert 2005). However, the 
topographical distribution of the metabolic alterations in both 
diseases differed, revealing a temporoparietal pattern for AD 
and a global, subcortically pronounced pattern for vascular 
dementia (Huang et al 2001; Heminghaus et al 2003). 
Furthermore, patients suffering from vascular dementia had 
remarkably enhanced TMA (tetramethylammonium)/Cr 
ratios, potentially due to ongoing degradation of myelin 
(Heminghaus et al 2003). These metabolite concentrations 
do not necessarily correlate with disease severity (Huang 
et al 2001).
With regard to patients at risk of AD, N-acetylaspartate 
and myo-inositol metabolite levels in patients with mild 
cognitive impairment are between those of cognitively 
normal subjects and patients with AD (Heminghaus et al 
2003). Patients who are positive for the apolipoprotein 
4 allele tend to demonstrate similar ﬁ  ndings prior to the 
onset of dementia or notable anatomical changes (Wahlund 
et al 2000; Mathis et al 2005). Longitudinal evaluation may 
allow determining prognosis and treatment in such at-risk 
patients. Also, MRS measurements have been shown to be 
a predictor of cognitive scores at follow-up in AD, but not 
in vascular dementia (Wahlund et al 2000). Furthermore, 
few controlled studies have used MRS to monitor treatment 
effects of muscarinic agonists and AchE inhibitors, demon-
strating N-acetylaspartate measured by MRS combined with 
hippocampal volumetry, to provide a highly useful surrogate 
marker of AD progression in trials of neuroprotective agents 
(Hossain et al 2002; Krishnan et al 2003).
The model proposed for the coupling between neuronal 
activity and CMRglc on the basis of studies at the cellular level 
would be consistent with an initial glycolytic processing of 
glucose occurring in astrocytes during NA, resulting in a tran-
sient lactate overproduction that is shuttled to axons where 
it is metabolized oxidatively to generate ATP, followed by a 
recoupling phase during which lactate would be oxidized by 
neurons (Mostert et al 2004). The spatio-temporal “window” 
during which a lactate peak could be detected by MRS would 
depend on the velocity and degree of recoupling between 
astrocytic glycolysis and neuronal oxidative phosphoryla-
tion (Mostert et al 2004). The possible role of lactate in 
dementia is currently under investigation: there seems to 
be experimental evidence in animal models that a parallel 
lactate and pyruvate increase reﬂ  ects a severe but not a light 
cognitive impairment (Pugliese et al 2005).
Difﬁ  culties remain in the clinical application – since 
MRS data acquisition from the whole brain is technically not Neuropsychiatric Disease and Treatment 2008:4(3) 600
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feasible, and ﬁ  ndings reported in studies may differ between 
particular regions (Kasischke et al 2004). It is also important 
for future MRS studies to clarify the spatial distribution of 
assessed metabolites and interaction between metabolites 
(Leybaert 2005).
Neuronuclear imaging in dementia 
assessment
Hundreds of patients with clinically diagnosed and in some 
cases histopathologically conﬁ  rmed AD have been studied 
using PET measurements of CBF and CMRglc or CMRO2 
(Jagust 2005) ﬁ  nding (i) a consistent pattern of focally 
decreased NA identiﬁ  ed with PET that involves neocorti-
cal association areas, but spares basal ganglia, thalamus, 
cerebellum, and the cortex processing primary sensory and 
motor functions (Mielke et al 1996; Herholz et al 1999); (ii) 
the extent of hypometabolism has been correlated with the 
severity of cognitive impairment and often shows right/left 
hemispheric asymmetry (Mielke et al 1996; Herholz et al 
1999); (iii) a decreased global CBF but normal oxygen 
metabolism (Wolf et al 1997); (iv) an increased striatal 
but not cortical metabolism (Rougement et al 1984). The 
“classic” regional cerebral pattern of bi-parietotemporal 
hypometabolism has been found to be associated with a 
high likelihood of AD, and typical patterns have also been 
identiﬁ  ed for many of the other entities, which may clini-
cally resemble AD, but are distinguished histopathologically 
(Mielke et al 1996). Blinded clinical evaluations of PET are 
capable of differentiating patients with AD from patients with 
other dementia or from cognitively intact persons (Mielke 
et al 1991). Effects of normal aging on brain function have 
also been examined with PET. Recent measurements using 
FDG-PET identified an age-related decline of glucose 
metabolism in healthy adults, most consistently in frontal 
cortex; studies of carefully selected subjects ﬁ  nd declines to 
be minimal in glucose metabolism throughout most of the 
brain areas during physiological aging (Zuchner et al 2004). 
(18)F-FDG PET indicates that AD-related processes lead 
to an altered functional relationship between the entorhinal 
cortex and several cortical and limbic regions, with respect 
to normal aging (Mosconi et al 2004). These results suggest 
that the assessment of coupled CMRglc reductions between the 
entorhinal cortex and the ipsilateral inferior temporooccipital 
cortex, besides the typical pattern of cortical reduction, could 
increase [18F]-FDG PET diagnostic sensitivity and further 
underline its inclusion in the clinical assessment of AD in 
the near future (Mosconi et al 2004). However, the relatively 
low spatial resolution of PET may hinder the detection of 
pathological elements in small anatomic structures, such as 
a layer of the entorhinal cortex or subdivision of the hip-
pocampus.
Single photon emission computed tomography (SPECT) 
has historically been the most widely available FIT, and has 
become the one most commonly employed in the clinical 
evaluation of dementia (Mirzaei et al 2004). Most SPECT are 
perfusion-based. Although the speciﬁ  c radiopharmaceuticals 
and technique differ from those used in PET, the principles 
of interpretation, as well as the neurobiological processes 
underlying its use, are similar. The practical differences in 
its application are (i) a typically worse spatial resolution of 
SPECT compared with PET, and (ii) an occasional uncou-
pling between cortical metabolism (usually measured with 
PET) and perfusion in the presence of certain CVD. Thus, AD 
studies utilizing SPECT yielded results similar to those using 
PET, but with less sensitivity and overall accuracy (Ota et al 
2005). That expectation has been further underlined through 
side-by-side comparisons of the two modalities, including 
studies performed in AD with mild symptoms, and with high-
resolution SPECT and PET (Silverman et al 2004).
A recent study assessing the accuracy of SPECT in early 
dementia followed patients longitudinally for a minimum of 
2 years after obtaining SPECT with 99mTC-HMPAO (Kemp 
et al 2003). Comparing the SPECT of one group progressing 
to probable AD, and the other remaining stable for at least 
two years, both subgroups matched for mildness at time of 
presentation, the progression group can be distinguished from 
the stable group with a sensitivity of 78% and a speciﬁ  city 
of 71% (Kemp et al 2003). A similarly designed study with 
PET has recently found that progression and nonprogression 
patients could be distinguished on an average of 3.0 years in 
advance with a sensitivity of 93% and a speciﬁ  city of 74% 
(Nestor et al 2003). The higher diagnostic and prognostic 
sensitivity of PET may be especially relevant in identifying 
the disease in its earliest stages, in order to target patients 
for therapy when neurodegeneration is minimal (Nestor et al 
2003). PET may have high diagnostic accuracy, but adding it 
to the standard diagnostic regimen of AD would yield limited, 
if any, beneﬁ  ts at very high costs (McMahon et al 2003).
Genetic risk factors for AD have been identiﬁ  ed. The 
4 allele of the apolipoprotein E gene is associated with a 
signiﬁ  cantly increased risk of developing AD of senile onset; 
overall, those with the  4/ 3 or  4/ 4 genotype are more than 
twice as likely to have AD compared with individuals with 
the  3/ 3 genotype (Mosconi et al 2005). FDG-PET have 
linked the  4 allele to hypometabolism in the posterior cin-
gulated, parietal, and temporal cortex, and have identiﬁ  ed Neuropsychiatric Disease and Treatment 2008:4(3) 601
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greater metabolic asymmetry in nondemented relatives of 
individuals with probable AD (Lee et al 2003). Furthermore, 
signiﬁ  cant metabolic decline in these regions has been 
observed in those who have inherited the  4 allele measured 
by repeated PET in the same subjects over a 2-year interval 
(Lee et al 2003).
The majority of PET in the memory-impaired popula-
tion used FDG as a radiolabeled tracer. Most recently, a 
new radiolabeled tracer, known as 2-(1-{6-[2-[18F]ﬂ  uoroe
thyl(methyl)amino]-2naphthiyl}ethylidene)malononitrile 
or [18F]FDDNP, has been developed (Nordberg 2004). This 
tracer is reported to target the amyloid-β senile plaques and 
neuroﬁ  brillary tangles in AD (Nordberg 2004). Additional 
ligands are in the preclinical development phase.
Neuronuclear imaging of neurotransmitter system
The acetylcholine system
A direct demonstration of cholinergic receptor function, 
however, may provide a method to select patients for 
treatment (Herholz et al 2004; Zuchner et al 2005) as cho-
linergic mechanisms have been shown to control amyloid 
precursor protein processing and the number of muscarinic 
M2-acetylcholine receptors is decreased in brain regions 
of patients with AD enriched with senile plaques (Zuchner 
et al 2005). Similarly, demonstration of treatment effects 
on neurochemical changes of cellular levels by IT will be 
important for the reﬁ  nement of pharmacotherapy in dementia 
(Smith et al 2003). Both, presynaptic deﬁ  cits to determine 
the possible need for cholinergic therapy and post-synaptic 
deﬁ  cits to assess the likelihood of successful response have 
to be studied (Herholz et al 2004). Two SPECT ligands 
are currently used: (i) iodobezovesamicol (IBVM) as a 
marker of ACh terminal density, which has successfully 
demonstrated marked reduction in patients with NINCDS 
diagnosed probable AD (Kuhl et al 1996). Studies have 
demonstrated that brain regions showing IBVM deﬁ  cits in 
AD are similar to those showing reductions in CMRglc and 
CBF using PET or SPECT (Kuhl et al 1996). 123I-(R,S)QNB 
(iodine-labeled 3-quinuclidinyl benzilate) or 123I-(R,R)QNB 
binds to muscarinic receptors (Wang et al 2005) and has been 
used to show that there is little receptor density reduction 
in patients with mild AD but varying degrees of reduction 
in moderate-to-severe AD.
The dopamine system
Speciﬁ  c SPECT ligands for dopamine transporter (FP-CIT, 
β-CIT, IPT, TRODAT) provides a marker for presynaptic 
neuronal degeneration (Marshall et al 2003). Striatal uptake 
correlates with disease severity, in particular bradykinesia 
and rigidity, and monitoring of progression assists in clini-
cal trials of potential neuroprotective drugs (Marshall et al 
2003). The dopamine transporter ligands β-CIT and FP-CIT 
are of particular interest in dementia, and both are labeled 
with iodine-123 (Donnemiller et al 1997). The main differ-
ence between these compounds is the recommended imaging 
time, which is 24 hours post-injection for β-CIT and around 
5 h for FP-CIT (Marshall et al 2003). Although the most 
obvious use of these compounds is the early detection of 
Parkinson disease and differentiation from similar presen-
tations such as essential tremor and vascular parkinsonism, 
another likely application is the differentiation of DLB from 
AD (Marshall et al 2003): abnormal results in DLB, normal 
in AD. Features of DLB, the second most common cause 
of degenerative dementia, include progressive cognitive 
deterioration, often associated with levodopa-unresponsive 
parkinsonism, fluctuations of cognitive functions, and 
psychotic symptoms (visual and auditory hallucinations, 
depression) (Marshall et al 2003). In a study of both CBF 
and dopamine transporter binding (using β-CIT), a subtle dif-
ference in perfusion patterns was found and a greater degree 
of occipital hypoperfusion was found in DLB as compared 
with AD (Donnemiller et al 1997).
Techniques for imaging amyloid-β in vivo
Imaging of AD progression would greatly facilitate the 
discovery of therapeutics, and a wide range of ligands are 
currently under investigation for the AP detection by PET 
(Lockhard et al 2005) (see Table 1 and Table 2).
Table 1 Comparison of techniques for in vivo imaging of amyloid β (Bacskai et al 2002)
Technique Cross-sectional  Ionizing   Volume  Invasivness
 resolution  (mm)1) radiation
PET 2–6  Yes  Entire  brain  No
SPECT 1–10  Yes  Entire  brain  No
MRI 0.1–1  No  Entire  brain  No
Multiphoton 0.001  No  0.2  mm3 Yes
Abbreviations: PET, positron emission tomography; SPECT, single photon emission computed tomography; MRI, magnetic resonance imaging; mm, millimetre.Neuropsychiatric Disease and Treatment 2008:4(3) 602
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The requirements for successful amyloid detection and 
quantiﬁ  cation include the availability of an AP-speciﬁ  c 
radioligand that incorporates a PET radionuclide within its 
structure (Lockhart et al 2005). As spatial resolution of PET 
is relatively low, PET is unable to detect individual receptors, 
PET will not depict individual plaques (Lockhart et al 2005). 
Instead, PET should provide a quantiﬁ  cation of the amyloid 
density in different brain regions and demonstrate differences 
between regions containing high and low densities of AP 
(Lockhart et al 2005). AP-Imaging can provide objective 
measures of preclinical disease state, when its changes in 
the follow-up are measured serially (Ono et al 2005). Such 
information can be used in prevention trials or in monitoring 
of progression and effectiveness of AD treatment.
Different strategies are used to develop compounds 
suitable for AP-IT in humans (Ono et al 2005). Monoclonal 
antibodies against AP or peptide fragments have limited 
the up-take by the brain when tested in patients with AD 
if tested for immune therapy of AD (Geylis et al 2005). 
When putrescine-gadolinium-β-amyloid has been injected 
into transgenic mice over-expressing amyloid, labeling has 
been observed with MRI (Vanhoutte et al 2005) creating an 
opportunity for the noninvasive investigation of the longi-
tudinal development of the plaques in animals and perhaps 
humans. The small molecular approach for AP-IT has so far 
been most successful (Higuchi et al 2005). The binding of 
different derivatives of Congo red and thioﬂ  avin has been 
studied in human autopsy brain tissue and in transgenic 
mice (Nordberg 2004). Agents that recognize AP should 
improve imaging contrast and detection sensitivity (Higuchi 
et al 2005). Suitable agents for detection of AP must meet 
several criteria: (i) the compound must bind to AP with high 
speciﬁ  city; (ii) the reagent must pass the BBB in sufﬁ  cient 
amounts to allow detection (Maccioni et al 2004). This 
requires that the compound is relatively small and lipophilic 
(Nordberg 2004). The reagent should bind with high afﬁ  n-
ity to allow retention of the compound speciﬁ  cally bound 
to AP while the free and nonspeciﬁ  cally bound compound 
clears from brain (Maccioni et al 2004). Two compounds, 
ﬂ  uorine-18-labelled-FDDNP and carbon-11-labelled-PIB, 
both show more binding in the brains of patients with AD 
than in those of healthy people (Nordberg, 2004). Attempts 
have been made to detect amyloid using [18F]FDDNP, labeled 
senile plaques and perineuronal nets in tissue sections from 
AD brain; however, speciﬁ  city for these neuropathological 
lesions is not clear (Agdeppa et al 2001). Perineuronal nets 
are a specialized form of extracellular matrix and consist of 
large aggregating chondroitin sulfate proteoglycans, with 
hyaluronan and tenascin as main components, which sur-
round subpopulations of neurons (Morcarski et al 2004). The 
glycosaminoglycan components of perineuronal nets form 
highly charged structures in the direct microenvironment of 
neurons and thus might be involved in local ion homeostasis 
(Morcarski et al 2004).
Taken together, perineuronal nets store associative 
memory, do not involve long-term potentiation, and are also 
loci for AD pathophysiology contributing to or causing early 
memory loss in clinically manifested AD (Alkon 1999). PET 
revealed good BBB permeability, and a sufﬁ  cient bioavail-
ability of different radiolabelled probes in AD patients as 
compared to controls (Agdeppa et al 2001; Niwa et al 2002). 
Unfortunately, nonspeciﬁ  c accumulation of the very lipo-
philic [18F]FDDNP is high in white matter areas (Nordberg 
2004). [18F]FDDNP initially accumulates most in the pons 
(an area without signiﬁ  cant numbers of plaques or tangles) 
and least in the hippocampus (an area of severe pathology) 
(Nordberg 2004).
Besides the ﬁ  rst steps of 19F and 1H MRI using a ﬂ  uo-
rine-containing probe in animals (Higuchi et al 2005), no 
method that does not involve artiﬁ  cially breaking the BBB 
has captured AP in vivo with sufﬁ  cient sensitivity and 
speciﬁ  city throughout the brain in a deﬁ  nitive manner that 
could be conﬁ  rmed by subsequent immunohistochemestry. 
Continuing engineering efforts to improve spatial resolution 
are underway in MRI, which may enable IT of individual 
plaques with contrast probes (Paduslo et al 2002) enabling 
early diagnosis and also provide a direct measurement 
of the efﬁ  cacy of antiamyloid therapies currently being 
developed.
Microscopy
In vitro studies indicate that amyloid plaques contain multiple 
binding sites that can accommodate structurally diverse 
Table 2 Agents for in vivo imaging of amyloid-β (Bacskai et al 
2002)
Imaging agent  Imaging   Signal-to-noise ratio
 technique
Thioﬂ  avin  Multiphoton  High
Thiazine Red R  Multiphoton  High
MeO-XO4 Multiphoton  High
BTA-1 Multiphoton  High
[18F]FDDNP PET  Low
Aβ peptides  Multiphoton  Moderate
Antibodies Multiphoton  Very  high
Abbreviations: BTA-1, thioﬂ  avin T; PET, positron emission tomography; FDDNP, 
[(2-ﬂ  uoroethyl)(methyl) amino]-2-naphthyl]ethzlidene)malnonitrile.Neuropsychiatric Disease and Treatment 2008:4(3) 603
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compounds, providing ﬂ  exibility for radiopharmaceutical 
design of AP imaging agents (Mathis et al 2004). Compared 
with large biomolecules, small molecule radiotracers are 
often readily accessible through chemical synthesis and can 
display superior brain permeability (Christie et al 2001). 
Several small molecule AP-imaging radioligands display high 
binding afﬁ  nities to AP and sufﬁ  cient brain penetration for 
imaging studies (Bacskai et al 2003; D’Amore et al 2003). 
Very speciﬁ  c detection of AP can be obtained with antibodies 
targeted against AP (D’Amore et al 2003). Antibodies 
enter the CNS in very small amounts when administered 
peripherally but have not been successfully used for IT yet 
(Christie et al 2001). However, ﬂ  uorescently labeled anti-AP 
antibodies were applied directly to the brains of transgenic 
mice and were detected with multiphoton microscopy 
(D’Amore et al 2003). The antibodies labeled AP within a few 
hundred micrometers from the surface of the cortex with high 
sensitivity and speciﬁ  city (Bacskai et al 2003). Surprisingly, 
also a rapid clearance of the labeled AP has been demonstrated, 
conﬁ  rming the usability of an immunotherapeutic approach to 
treat AD (Christie et al 2001). It is possible that manipulations 
that increase BBB permeability for labeled antibodies would 
further improve IT.
Multiphoton microscopy allows very high resolution 
(0.001 mm) imaging of microsopic structures with high 
sensitivity (Bacskai et al 2003). This light microscope-based 
technique depends on detecting ﬂ  uorescence (either autoﬂ  uo-
rescence or from a contrast reagent), though no radioactive 
tracers are necessary (Christie et al 2001) using a pulsed near-
infrared laser to excite ﬂ  uorescence for deeper penetration 
than visible light microscopy not scattering tissue, and optical 
tomography with restricted excitation volume (Christie et al 
2001). The technique depends on an invasive technique to 
allow access to the brain, and imaging depths of about 500 µm 
are achievable leading to a very small imaging volume within 
the cortex compared to the size of the brain (Christie et al 
2001). Fluorescent contrast reagents with high speciﬁ  city 
result in very high contrast images of immunohistochemically 
deﬁ  ned microscopic structures (Christie et al 2001; Bacskai 
et al 2003) allowing direct examination of the natural his-
tory of plaques and evaluation of antiplaque therapeutics in 
models of AD (Bacskai et al 2002, 2003).
In vivo imaging has been performed with ﬂ  uorescent 
derivatives of thioﬂ  avin T and Congo red (Nordberg 2004). 
Both compounds have been used as histochemical stains for 
ﬁ  brially amyloid-β deposits: They are small, lipophilic deri-
vates and enter the brain rapidly. Multiphoton microscopy is 
used to identify the labeled plaques in transgenic mouse brain 
30 min after intravenous injection or 24 h after intraperitoneal 
injection (D’Amore et al 2004). The ﬂ  uorescent reagents 
specifically labeled senile plaques and cerebrovascular 
amyloid (Nordberg 2004). They have near ideal properties 
for AP-imaging, and multiphoton microscopy demonstrates 
that these compounds label immunohistochemically deﬁ  ned 
AP in transgenic mice over-expression of mutant human 
amyloid precursor protein (D’Amore et al 2004). Radiola-
bel led versions of methody-XO4 and BTA-1 may also be 
excellent candidates for PET in AD (Schmidt et al 2001; 
Kleindienst et al 2004).
Functional imaging methods other than 
single photon emission tomography 
and positron emission tomography
FMRI offers a method to indirectly measure functional brain 
changes associated with NA (Goekoop et al 2004, 2006) 
being similar in its use to PET (Nair 2005). Both methods are 
able to indirectly measure NA in individual patients because 
of changes in blood properties (Nair 2005). The main type of 
fMRI is the blood oxygen level dependent (BOLD) imaging 
which does not involve the injection of paramagnetic con-
trast agents and is based on differences in the paramagnetic 
properties between oxy- and deoxyhemoglobulin to detect 
regional differences in blood oxygenation, usually in com-
parison between a NA and a resting task (Rombouts et al 
2005). BOLD contrast MRI is a simple noninvasive method 
of estimating “perfusion”, and combined with a vasodilatory 
stimulus, may allow estimation of cerebral vascular reserve 
(Nag 2003). BOLD signal change appears to originate from 
net changes in averaged NA areas of cortex that trigger, 
in some manner, CVC leading to the measured response 
(Nag 2003). A question directly relevant to imaging AD is 
whether this coupling is intact and if it is possible to make 
quantitative comparisons between individuals and groups 
(Gonzalez 1996).
In addition, pharmacological fMRI may help to exam-
ine neurochemical changes – ie, of the cholinergic system 
(Goekoop et al 2004) – in early disease of AD by studying 
signal reactivity to pharmacological challenge at cellular 
levels. In addition, a recent study using fMRI showed 
increased brain activation during memory tasks in APOE-4 
carriers in brain regions affected by AD (Small 2002). Such 
pharmacological MRI have implications for understanding 
the neurochemical mechanism by which cognitive enhancing 
medications exert these effects on brain function and for the 
use of fMRI in early detection and treatment monitoring of 
AD (Goekoop et al 2006).Neuropsychiatric Disease and Treatment 2008:4(3) 604
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FMRI and examining brain-behavior relationships are 
recent IT that contribute to dementing illness and are notably 
improving our understanding of the pathophysiology of the 
different subgroups of dementia (Goekoop et al 2006). The 
results of fMRI of cognitively impaired or at-risk patients 
have shown increases or decreases in the intensity and extent 
of NA, as compared with ﬁ  ndings in control groups (Johnson 
et al 2005). The discrepancies between increased or decreased 
NA may have to do with either differing task demands or 
different levels of compensatory reserve (Goekoop et al 
2006). In addition, the differential response to cholinergic 
challenge in mild cognitive impairment and AD visualized by 
fMRI may reﬂ  ect a difference in the functional status of the 
cholinergic system between both subgroups, which is in line 
with recent results showing a differential clinical response 
to cholinergic treatment (Goekoop et al 2006).
Three kinds of fMRI to study AD have emerged, all still in 
their developmental stages. One approach focuses on examin-
ing tasks, such as encoding information into recent memory, 
that are known to be compromised in AD (Goekoop et al 
2006). A second approach examines activation patterns that 
result from the performance of tasks that are completed suc-
cessfully but may be more difﬁ  cult in patients at risk for AD. 
The idea behind such an approach is that cognitive tasks can 
serve as “stress tests”, with individuals at the earliest stages of 
the disease requiring more neural activity to reach the same 
level of performance (Hotz 2001). A ﬁ  nal approach, which 
has been used in only a few preliminary studies performed to 
this point, is to image tasks that yield downstream markers 
of medial temporal function (Buckner et al 2000).
Diagnostic evaluation
CVD and stroke relate to a high risk of cognitive impair-
ment, but also relate to AD: vascular cognitive impairment 
and dementias extend beyond the traditional multi-infarct 
dementia (Table 3). The pathophysiology of vascular 
dementias includes interactions between vascular etiolo-
gies (CVD and vascular risk-factors), changes in the brain 
(infarcts, white matter lesions, atrophy), host factors (age) 
and cognition (Schaller 2004a). Variation in deﬁ  ning the 
cognitive syndrome, in vascular etiologies, and allowable 
brain changes in current criteria have resulted in variable 
estimates of prevalence, of subgroups of subjects, and of 
the subtypes and distribution of putative causal brain lesions 
(Lee et al 2003).
Subcortical ischemic vascular disease and dementia 
incorporate small vessel disease as the main vascular etiol-
ogy, lacunar infarct and ischemic white matter lesions as 
primary type of brain lesions, subcortical location as the 
primary location of lesions, and subcortical syndrome as 
the primary clinical manifestation (Solerte et al 2002). It 
incorporates two clinical entities, “Binswanger’s disease” 
and “the lacunar state” (Jellinger 2002). AD with vascular 
dementias (mixed dementia) has been underestimated as a 
prevalent cause in the older population (Jellinger 2005). In 
addition to simple co-existence, vascular dementia and AD 
have closer interaction: several vascular risk factors and 
vascular brain changes relate to clinical manifestation of 
AD, and they also share common pathogenetic mechanisms 
(Langa et al 2004). Vascular cognitive impairment is a 
category aiming to replace the “Alzheimerized” dementia 
concept in the setting of CVD, and substitute it with a spec-
trum that includes subtle cognitive deﬁ  cits of vascular origin, 
post-stroke dementia, and the complex group of the vascular 
dementias (Erkinjunttti et al 2004; Mirzaei et al 2004). So 
far, there is no standard treatment for vascular dementias, 
and still little is known about the primary prevention (brain 
at risk for CVD) and secondary prevention (CVD-brain at 
risk for vascular cognitive impairment/vascular dementia) 
(Roman et al 2000). Future focus should be directed to the 
distinct etiological and pathological factors: the vascular 
and the AD burden of the brain; the state-of-the-art-imaging, 
and especially the molecular imaging, has a main place in 
this research.
Table 3 Use of different imaging methods to investigate the 
neurovascular mechanism in Alzheimer’s disease (Lee et al 2003)
Technique Indications and role
Routine examinations
CT/MRI Exclusion of disease, anatomy
MR volumetrics Hippocampal atrophy
Semiroutine examinations
SPECT/PET Global/regional blood ﬂ  ow, metabolic changes
DWI Global/regional dysfunction
Research
MR volumetrics Frontal/temporal lobe atrophy, whole brain atrophy; 
sequential: rate of volume loss
MRS Neuronal loss, abnormal metabolite
DTI Neuronal integrity
fMRI Memory, associative functional dysfunction
Abbreviations: CT, computed tomography; MRI, magnetic resonance imaging; MR, 
magnetic resonance; SPECT, single-photon-emission computed tomography; PET, 
positron emission tomography; DWI, diffusion weighted imaging; MRS, magnetic 
resonance spectroscopy; DTI, diffusion tensor imaging; fMIR, functional magnetic 
resonance imaging.Neuropsychiatric Disease and Treatment 2008:4(3) 605
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Early detection of Alzheimer’s disease
PET has been used to directly quantify several processes 
relevant to the status of cerebral health and function, includ-
ing CBF, cerebral blood volume, CMRO2, and CMRglc 
demonstrating diagnostic and prognostic use in evaluating 
patients who have cognitive impairment, and in distinguish-
ing among primary neurodegenerative dementias and other 
causes of cognitive decline (Silverman et al 2005). These 
PET found, that patients with AD may differentially express 
resting CBF covariance patterns even at very early disease 
stages (Scarmeas et al 2004). Expression of covariance pat-
terns correlates with cognitive and functional performance 
measures, holding promise for meaningful associations with 
underlying biopathological processes (Eustache et al 1997; 
Herholz et al 2000).
Ishii and colleagues (2000, 2001) demonstrated deﬁ  cits 
in perfusion and metabolism, using 18FDG and H2
15O PET 
in mild AD: at the mild and moderate stages of AD, glucose 
metabolism is reduced not only in the parietotemporal region 
but also in the posterior cingulate and precuneus. At the 
advanced stage of AD, there is also a metabolic reduction 
in the frontal region (Herholz et al 2000). In AD patients, 
CMRglc is relatively preserved in the pons, sensorimotor 
cortices, primary visual cortices, basal ganglia, thalamus 
and cerebellum (Herholz et al 2000). Recent investigations 
revealed that asymptomatic members of AD families have 
signiﬁ  cant parietal and temporal deﬁ  cits compared to control 
subjects, and that nondemented people in their mid-ﬁ  fties 
with increased genetic AD risk, as conferred by apolipo-
protein E allele  (apoE-4), have signiﬁ  cantly lower parietal 
metabolism than those without the apoE-4 allele (Mosconi 
et al 2005). Other brain regions typically affected by AD 
have also been reported to be hypometabolic in individu-
als homo- or heterozygous for apoE-4, including posterior 
cingulate, inferior parietal, temporal, and prefrontal regions 
(Mosconi et al 2005).
Differential diagnosis of Alzheimer’s 
disease
Neuropathology and structural MRI have pointed to the 
medial temporal lobe as the brain region earliest affected 
in AD (Jellinger 2002; Hund-Georgiadis et al 2003). T1-
weighted MRI ﬁ  ndings provide strong evidence that in mild 
cognitive impairments, AD-related volume losses can be 
reproducibly detected in the hippocampus, the entorhinal 
cortex and, to a lesser extent, the parahippocampal gyrus; 
they also indicate that lateral temporal lobe changes are 
becoming increasingly useful in predicting the transition to 
dementia (Mosconi 2005). The 3-D data acquisition in MRI 
enables exact calculation of volumes and coregistration of 
images during follow-up examination (Barkhof 2003). Perfu-
sion MRI may be performed to demonstrate areas of reduced 
CBV and CBF in vascular dementia and several forms of 
degenerative brain disorders (Barkhof 2003). The CBF reduc-
tion is multifocal and subcortical in vascular dementia and 
shows a cortical distribution in AD (Barkhof 2003). DWI 
and DTI of individuals with AD demonstrate changes in 
whole brain white matter and posterior ﬁ  ber tract with some 
evidence suggesting that the posterior ﬁ  ber tracts are more 
affected than anterior ﬁ  ber tract (Kantarci et al 2001). The 
pathophysiological basis of DTI effects remains uncertain. 
In addition, current experimental data suggests that magni-
tude and BOLD brain response in activated particular brain 
regions is different in AD (Bondi et al 2004). In addition, a 
diamine- and gadolinium-substituted derivative of β-amyloid 
is shown to have enhanced in vitro binding to AD AP and 
increased in vivo permeability at BBB because of the unique 
Asp/Glu substitutions (Paduslo et al 2004). Because of MRI 
contrast enhancement provided by gadolinium, MRI of indi-
vidual AP in AD brains allows for early diagnosis to other 
dementia subgroups and also provides a direct measure of 
the efﬁ  cacy of anti-AP therapies currently being developed 
(Vanhoutte et al 2005).
Failure of BBB with leakage of serum components into 
and through the walls of cerebral small vessels leading to 
neuronal and glial damage may be an important common 
mechanism in AD and vascular dementia (Zlokovic et al 
2004). Together with an intravenous paramagnetic contrast 
agent, such as gadolinium-DTPA, MRI can also detect and 
quantify BBB damage (Vlassenko et al 2006). Further studies 
are required to prove the hypothesis that BBB failure and 
perforating artery endothelial leakage might be a common 
pathogenetic mechanism for lacunar stroke, white matter 
hyperintensities, and dementia. If so, new treatments could 
be targeted toward this new pathophysiological mechanism 
to prevent the development of or to reduce BBB leakage.
FDG-PET has revealed glucose metabolic reductions 
in the parieto-temporal, frontal and posterior cingulate 
cortices to be the hallmark of AD (Mosconi 2005). Overall, 
the pattern of cortical metabolic changes has been useful 
for the prediction of future AD as well as in distinguishing 
AD from other neurodegenerative diseases (Mosconi 2005). 
FDG-PET on average achieves 90% sensitivity in identifying 
AD, although speciﬁ  city in differentiating AD from other 
dementias is lower (Mosconi 2005). Moreover, recent MRI-
guided FDG-PET have shown that medial temporal lobe Neuropsychiatric Disease and Treatment 2008:4(3) 606
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hypometabolism is the most speciﬁ  c and sensitive measure 
for the identiﬁ  cation of mild cognitive impairments, while the 
utility of cortical deﬁ  cits is controversial (Mosconi 2005).
Comparative accuracy of positron 
emission tomography
Since PET have shown that psychological or cognitive activa-
tion in mild-to-moderate AD can increase CBF and CMRglc as 
in normal subjects, a similar ﬁ  nding with BOLD fMRI would 
demonstrate not the quantity but the topographic pattern of 
activation to differentiate AD from normal persons.
Although the accuracy of the diagnosis is of critical 
importance, only few studies addressed this question by 
providing data of sensitivity and speciﬁ  city following a repre-
sentative patient mix (Kodama et al 2002). The sensitivity of 
other diagnostic methods is substantially lower than reported 
by PET, although the speciﬁ  city is comparable (Herholz et al 
2000; Mielke et al 2001).
In vivo proton MRS enables investigation of speciﬁ  c 
metabolites within tissues. A comparison between 31phos-
phorus MRS and FDG-PET in AD was unable to ﬁ  nd a cor-
relation between phosphorus metabolic and either glucose 
metabolic or dementia severity; hence, measurement of 
rCMRglc represents a promising technique, but with uncertain 
clinical speciﬁ  city and utility (Mielke et al 2001) suggesting 
that in AD reduced neuronal energy performance and mem-
brane abnormalities contribute to metabolic deterioration 
(Mielke et al 2001).
Prospects for the future
PET and SPECT has come to be quite useful for assessing 
therapeutical effects of newly introduced AD treatment 
(Matsuda 2001). A number of questions still need to be 
addressed; in particular the different time constants for syn-
aptic activity and the metabolic response as the basis of the 
signals detected with PET need to be considered (Matsuda 
2001). In this context, it is likely that the glutamate-mediated 
coupling at neuron-astrocyte metabolic units in an activated 
cortical area will be compounded through a mechanism in 
which the extracellular space acts as a spatial and temporal 
metabolic buffer (Matsuda 2001). The usefulness of these 
methods in the clinical routine is promising but there are no 
data that demonstrate whether they contribute a diagnostic 
value yet.
Different molecular IT may be useful not only to diagnose 
different subtypes of dementia but also to monitor therapeu-
tic efforts (Raszkiewicz et al 1992). For example, carriers 
of a common AD susceptibility gene have functional brain 
abnormalities in young adulthood, several decades before the 
possible onset of dementia. With the increasing options to 
treat dementia symptoms in the future, this aspect may gain 
increased interest, and IT may become more and more the 
target of experimental research (Raszkiewicz et al 1992).
Conclusion
Cerebral arteriosclerosis or stroke may increase the deposi-
tion of AP or the formation of neuroﬁ  brillary tangles. Alter-
natively, they may simply hasten the age at onset of disease, 
or increase the severity of disease symptoms. Disruption of 
this regulatory network occurs in response to brain injury, for 
example, during stroke. Evidence now indicates that cerebro-
vascular dysfunction is at least an aggravating, concomitant 
feature of neurodegenerative disorders such as AD. Accu-
mulation of AP is associated with neuronal death in AD. AP 
induces dysfunction in all cell types of the neurovascular unit 
and interferes with the function of blood vessels. These effects 
are mediated through reactive oxygen species. This raises the 
provocative question of whether AD is secondary to vascular 
dysfunction in the CNS and, therefore, the neurodegeneration 
that follows is a consequence of inadequate CBF, altered brain 
metabolism and failure in physiological functions of brain 
endothelium, which represents a site at the BBB.
AD IT opens the window to a new direction for experi-
mental research and clinical diagnosis or treatment of AD. 
This approach could be the basis of longitudinal studies in 
experimental models of AD to search for biomarkers associ-
ated with AP pathologies as well as to track disease course 
after treatment with candidate pharmacological substances.
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